CV

CURRICULUM VITAE

NAME: Gary David LOPASCHUK DATE OF BIRTH: June 4, 1955 PRESENT ADDRESS: Cardiovascular Research Centre 423 Heritage Medical Research Centre The University of Alberta Edmonton, Alberta T6G 2S2 Tel: (780) 492-2170 Fax: (780) 492-9753 E-mail: gary.lopaschuk@ualberta.ca PRESENT POSITION: Distinguished University Professor, Departments of Pediatrics and Pharmacology Faculty of Medicine & Dentistry, University of Alberta AHFMR Scientist CITIZENSHIP: Canadian MARITAL STATUS: Married, three children EDUCATION: 1973-1978 B.Sc. (Pharmacy), University of British Columbia 1978-1980 MSc (Pharmacology and Toxicology, Pharmaceutical Sciences), University of British Columbia Supervisor: Dr. S. Katz, Professor 1981 Mayo Clinic, Rochester, Minnesota, USA Special Projects Associate, Cell Biology. Supervisor: Dr. J.T. Penniston, Professor 1980-1983 PhD (Pharmacology and Toxicology, Pharmaceutical Sciences), University of British Columbia Supervisors: Dr. J.H. McNeill, Dean and Dr. S. Katz, Professor 1983-1985 Post-Doctoral Fellowship, The Milton S. Hershey Medical Centre Department of Physiology, Hershey, Pennsylvania, USA Supervisor: Dr. J.R. Neely, Professor

CV

AWARDS: 1978 Warner-Lambert Research Fellowship 1980-1983 Canadian Heart Foundation Research Traineeship Faculty of Pharmaceutical Sciences, University of British Columbia 1983-1985 Canadian Heart Foundation Post-Doctoral Fellowship The Milton S. Hershey Medical Centre, Hershey, Pennsylvania 1985-1990 Canadian Heart Foundation Scholarship The Hospital for Sick Children, Toronto, Ontario and the University of Alberta. 1986 University of Toronto, Dean's General Award 1988 Canadian Cardiovascular Society, Young Investigator Award 1989-1994 Alberta Heritage Foundation for Medical Research Scholarship 1989 International Society for Heart Research Runner-Up for Bing Award 1990 Awarded Tenure, Faculty of Medicine, University of Alberta 1993 Merck-Frost Research Award, Pharmacological Society of Canada 1993-1998 Medical Research Council of Canada Scientist Award 1994-1999 Alberta Heritage Foundation for Medical Research Senior Scholarship 1999-2010 Alberta Heritage Foundation for Medical Research Medical Scientist 2007 Fellow - Royal Society of Canada 2007 Canadian Cardiovascular Society Research Achievement Award 2008 Finalist - AsTech Awards 2008 Alberta Heritage Foundation for Medical Research 20-Year Funded Personnel Award 2008 BioAlberta 2008 Leadership in Science & Innovation Award 2010 Distinguished University Professor Award, University of Alberta 2014 Norm Alpert Research Achievement Award. European Section of the

International Academy of Cardiovascular Sciences. October 8-11, 2014. Balatongyörök, Hungary.

CV

POSITIONS HELD: 1985-1986 Assistant Professor of Paediatrics and Pharmacology The Hospital for Sick Children and the Faculty of Medicine, University of Toronto, Toronto, Ontario 1986-1990 Assistant Professor of Paediatrics Faculty of Medicine, University of Alberta, Edmonton, Alberta 1987-1990 Assistant Professor of Pharmacology, Dept. of Pharmacology, University of Alberta, Edmonton, Alberta 1987- Investigator, Cardiovascular Disease Research Group 1987- Scientific and Research Associate (Medical Director) University of Alberta Hospitals 1990- Investigator, Muttart Diabetes Research Centre 1990-2000 Investigator, Lipid and Lipoprotein Research Group 1992- Investigator, Perinatal Research Centre 1990-1994 Associate Professor of Paediatrics and Pharmacology University of Alberta, Edmonton, Alberta 1994- Professor of Paediatrics and Pharmacology University of Alberta, Edmonton, Alberta 1995-2000 Director of Research, Department of Pediatrics 1997-2008 Director, Cardiovascular Research Group 2004-2008 Project Leader, CFI “Cardiovascular Translational Research Centre” 2006-2012 Scientific Director, Mazankowski Alberta Heart Institute 2010-2017 AHFMR Scientist Award 2010- Distinguished University Professor, University of Alberta 2014/10- Interim co-director Applied Research, Cardiovascular Translational Science Institute University of Alberta 2015- President, International Society for Heart Research, North American Section 2015- Associate Chair of Research, Department of Pediatrics, Univ. of Alberta

CV

GRANTS-IN-AID 1985-1988 Medical Research Council of Canada, $38,000/annum "Coenzyme A regulation of Cardiac Metabolism" 1986 Medical Research Council of Canada, $56,000, Equipment Grant 1986 Connaught Fund, University of Toronto, $20,000 I declined this award because of move to the University of Alberta. 1986 Central Research Fund, U. of Alberta, $7,500 1986-1990 Juvenile Diabetes Foundation International, $240,000. "Fatty acid metabolism during ischemia in the diabetic rat heart" 1988-1989 Special Services, U. of Alberta Hospitals, $29,000 "Protection of the Reperfused Myocardium" 1989-1991 Alberta Heritage Foundation for Medical Research, $127,000, Establishment Grant. 1989-1992 Nordic Laboratories $108,000, "TA-3090 in the Ischemic Heart" 1990-1998 Medical Research Council, $79,000/annum "Energy Substrate Metabolism in the Ischemic and Non-ischemic heart" 1991-1992 Muttart Diabetes Research and Training Centre, $9,000 "Arachidonic Acid Production and Phospholipids Sources in Islets", Co-Investigator: Dr. A. Rabinovitch 1991-1993 Canadian Diabetes Association, $56,500/annum "Metabolic Protection during Myocardial Ischemia in the Diabetic" 1992-1993 Sigma-Tau, $69,000 "Effects of Carnitine on Myocardial Metabolism in Hypertrophied Hearts" 1992-1995 Syntex (Contract), $60,000/annum "Ranolazine Effects on Myocardial Metabolism" 1992-1993 Special Services Research Comittee, $3,000 "Use of Dichloroacetate in Cardiac Bypass

Patients" 1993 Alberta Heritage Foundation for Medical Research, $20,000 Equipment Grant. 1993-1996 CIBA-GEIGY, $153,000/annum "Identify Novel Approaches towards Minimizing Injury in the Reperfused Ischemic

Heart" Co-investigators: Drs. A. Clanachan and R. Shulz 1993-1995 Juvenile Diabetes Foundation International, $66,000/annum, "Regulation of Fatty Acid

Oxidation by Acetyl CoA Carboxylase in the Diabetic Rat Heart" 1994 Medical Research Council Equipment Grant $225,000, Primary Investigator: Dr. Paul

Armstrong, Co-investigators: Drs. Jugdutt, Kavanagh, Lopaschuk

CV

1994 Alberta Heritage Foundation for Medical Research, $30,000 equipment grant Co-applicants: Drs. Michalak, Fliegel and Schulz 1995-1997 Tahio Pharmaceuticals, $42,000 "Effects of MET-88 on myocardial energy metabolism" 1995-1999 Canadian Diabetes Association, $60,000/annum "Regulation of Fatty Acid Oxidation

by Acetyl CoA Carboxylase in the Diabetic Rat Heart" 1996-1997 Servier, $112,000 “Effects of trimetazidine on myocardial energy metabolism” 1996-1997 CV Therapeutics, $41,000 “Ranolazine effects on fatty acid oxidation” 1996-1999 Alberta Heart and Stroke Foundation, $60,000/annum "Myocardial Metabolism in the Fetus and Newborn 1997-2000 CIHR, $56,000/annum, “The Source and Fate of Protons in the Reperfused Heart.” Principal Investigator: Dr. G.D. Lopaschuk; Co-investigator: Dr. S. Clanachan 1998 Alberta Heritage Foundation for Medical Research, $38,277 Equipment Grant 1998-2001 CIHR Group Grant, Core Budget $147,000/annum “Cardioprotection during

and following ischemia.”Director: Dr. G.D. Lopaschuk Members: Drs. R. Schulz, B. Jugdutt, M. Allard, R. Brownsey, A.S. Clanachan 1998-2003 CIHR, $74,741annum, "Energy Substrate Metabolism in the Ischemic and Non-ischemic heart" 1999-2001 Canadian Diabetes Association, $56,000/annum "Malonyl CoA Control of Fatty Oxidation in the Diabetic Rat Heart" 1999-2002 Alberta Heart and Stroke Foundation, $51,000 "Energy Metabolism in the Newborn heart 1999-2002 Metabolic Modulators Research Ltd., $47,000, Characterization of Malonyl CoA

decarboxylase, 2000-2001 Pfizer, $89,000 “Biochemical and pharmacological characterization of cardiac 5’AMP

– Activated protein kinase (AMPK-Kinase AMPKK)” 2001-2003 Canadian Diabetes Association, $75,000/annum “PPAR control of cardiac fatty acid oxidation in the diabetic heart” 2001-2003 CIHR, $108,000/annum“Control of glucose metabolism in the fetal and newborn heart” Principal Investigator: Dr. I. Rebeyka Co-investigator: Dr. G.D. Lopaschuk 2001-2003 CIHR Training Program “Strategic Training Program in Maternal-Fetal-Newborn

Health” Director: Dr. David Olson Members: Drs. Lopaschuk, Guilbert, Greer, Morrish, Archer and Mitchel

CV

2001-2004 CIHR, Group Grant, $184,231/annum “Perinatal Health and Disease” Director: Dr. David Olson Members: Drs. Lopaschuk, Guilbert, Greer, Morrish, Archer and Mitchel 2001-2004 CIHR, Core Budget $210,000/annum “Cardioprotection during and following

ischemia.” CIHR Group Grant: Director: Dr. G.D. Lopaschuk Members: Drs. R. Schulz, B. Jugdutt, P. Light, K. Kavanagh, A.S. Clanachan, J. Dyck 2001-2006 CIHR, $118,000/annum, “The Source and Fate of Protons in the Reperfused Heart.” Principal Investigator: Dr. A.S. Clanachan, Co-investigator: Dr. G.D. Lopaschuk 2002 Alberta Heritage Foundation for Medical Research, $37,500, Equipment Grant 2002 CFI, AHFMR, U. of Alberta Hospitals $14,000,000 Heart and Stroke Translational Research Center Director: Dr. S. Archer, Dr. Lopaschuk, Co-investigator 2002-2003 CIHR, Proof-of Principle, $100,000 “Commercilization of novel compounds that stimulate glucose metabolism in the heart” 2002-2005 Alberta Heart and Stroke Foundation, $51,000/annum "Energy Metabolism in the Newborn heart” (Declined due to CIHR Award) 2002-2005 CIHR, $84,000 / annum "Energy Metabolism in the Newborn heart” 2002-2008 CIHR Training Program TORCH, $213,000/annum Director: Dr. P. W. Armstrong, Dr. Lopaschuk, Co- investigator 2003-2005 Canadian Diabetes Association, $72,200/annum “PPAR Control of Cardiac Fatty Acid Metabolism in the Diabetic.” 2003-2008 CIHR, $118,000/annum “Energy Substrate Metabolism in the Ischemic and Non-Ischemic Heart” 2004-2009 CIHR, Core Budget $236,000/annum, “Cardioprotection during and following

ischemia.” CIHR Group Grant: Director: Dr. G.D. Lopaschuk, Members: Drs. R. Schulz, P. Light, B. Finegan, A.S. Clanachan, J. Dyck, PY Cheung, M. Allard

2004-2009 Canadian Foundation for Innovation, ASRIP $14,800,000 Cardiovascular Translational Research Centre 2005-2010 CIHR, $118,531/ annum "Energy Metabolism in the Newborn heart” 2006-2007 CIHR, $97,500 “Altering hypothalamic malonyl CoA to treat obesity and insulin

resistance”. 2006-2009 HSFC, $57,000/annum “Cardiac lipotoxicity in obesity and diabetes” 2007-2012 CIHR, $118,000/annum, “AMP-activated protein kinase effects on the source and fate

of protons in the ischemic heart”

CV

2008-2011 Canadian Diabetes Association, $66,300/annum, “Hypothalamic arcuate malonyl CoA

control of food intake and body energy balance” 2008-2013 CIHR, $124,000/annum “Energy substrate metabolism in the ischemic and non-

ischemic heart” 2009 - 2015 HSFA, $47,500/annum “The metabolic basis of heart failure in obesity” 2012-2015 Canadian Diabetes Association, $100,000/annum “Hypothalamic malonyl CoA control

of obesity” 2012-2017 CIHR, $124,000/annum “Energy metabolism in the newborn heart” 2014-2019 CIHR, $125,600/annum, “Energy substrate metabolism in the ischemic and non-

ischemic heart” 2014-2017 CFI - AB Enterprise and Advanced Education, $391,584 Equipment Grant

“Physiological and oxygen sensing suite for ex vivo and in vivo studies” 2015-2016 Women and Children’s Health Research Institute, $50,000 “Acetylation control of

glucose and fatty acid oxidation in the human newborn heart” 2016-2021 CIHR, $98,000/annum, “Effect of obesity on cardiac energy metabolism in heart

failure” PROFESSIONAL ACTIVITIES: Scientific Review Committees: 1986-1988 Member, Scientific Review Committee (Senior Personnel) Canadian Heart Foundation 1991-1992 Member of the Scientific Review Committee, Heart and Stroke Fdn. of Canada 1992-1997 Scientific Officer, Scientific Review Committee, Heart and Stroke Fdn. of Alberta 1993-1996 Chairman, Junior Personnel Review Committee, Heart and Stroke Fdn. of Canada 1993-1996 Member, Personnel Review Committee, Canadian Diabetes Association 1993-1996 Member, Studentship Committee, AHFMR Scientific Officer, Scientific Review Committee, Heart and Stroke Foundation of Alberta 1994-1999 Member, Cardiovascular A Grants Committee, Medical Research Council 1994-2000 Member, Cardiovascular B Grants Committee, Medical Research Council 1995-1999 Chairman, Research Grant Review Committee, Children Health Centre Foundation 1996-2001 Member, Grant Review Committee, Canadian Diabetes Association 1999-present Member, CIHR University /Industry Grant Committee Chairman, Scientific Review Committee, Heart and Stroke Foundation of Canada 2000-2001 Member, NIH Study Section 1997-2002 Chairman, Scientific Review Committee, Heart and Stroke Foundation of Alberta 2004-2010 Member, NIH “Metabolism and Myocardial Ischemia” Study Section 2006-2008 Chair, Personal Program Review Task Force, Heart and Stroke Foundation of Canada 2008-2010 Member, CIHR/ HSFC IMPACT “Integrated and Mentored Pulmonary and Cardiovascular Training 2008- Chair, Medical Advisory Board, Heart and Stroke Foundation of Alberta, N.W.T. and Nunavut 2009-2015 CIHR Proof of Principle Grant Review Panel 2011-2015 Member, Heart and Stroke Foundation of Canada Scientific Review Committee

CV

Editorial Board Membership: Editorial Board, Circulation Research (1997- ) Editorial Board, J Clin Invest (2012- ) Associate Editor, Am J Physiol, Heart (2011-) Associate Editor, Canadian Journal of Physiology and Pharmacology (1993- ) Editorial Board, Cardiovascular Research (1995-2001, 2010-) Editorial Board, Biochim. Biophys. Acta (2008- ) Editorial Board, Heart and Metabolism (1999- ) Editorial Board, Cardiovascular Drugs and Therapy (2004- ) Editorial Board, Am J Physiol, Endocrinology (2005- ) Editorial Board, Basic Research in Cardiology (2009-) Journals to which paper reviews are routinely provided (Approximately 120-150 papers reviewed/year): J. Biol. Chem. Circ. Res. Am. J. Physiol. J. Clin. Invest. Circulation Science Nature Cell Metabolism J. Mol. Cell. Cardiol. Cardiovasc. Research Heart Failure Reviews Basic Res. Cardiol. Can. J. Cardiol. Diabetes Diabetologia Metabolism Biochim. Biophys. Acta Ped. Res. J. Am. College Cardiol. Biochemical J. Mol. Cell. Biochem. Heart and Metabolism Can. J. Physiol. Pharmacol. Obesity Granting agencies to which reviews are routinely provided: Canadian Institutes for Health Research B.C. Health Research Foundation Heart and Stroke Foundation of Canada National Science Foundation Canadian Diabetes Association National Institutes for Health Organizing/Strategic Planning Committee: 1992 Member, Heart and Stroke Foundation of Canada Career Development Strategic Planning Committee 1996-2002 Board of Directors, Heart and Stroke Foundation of Alberta 2000-2003 Member, Research Planning and Priorities Committee, Heart and Stroke Foundation of Canada Councillor, International Society for Heart Research 2001 Chairman, Organizing Committee, ISHR, Satellite Meeting of the XVII World Congress, Banff, AB. 2003-2007 Vice-Chair, Research Planning and Priorities Committee, Heart and Stroke Foundation of Canada 2012-2015 Member, Council on Mission: Priorities, Advices, Science and Strategy of the Heart and Stroke Foundation of Canada (CoMPASS) Membership in Societies: 1978 - College of Pharmacists of B.C. (retired registrar) 1979- Registered, Pharmacy Examining Board of Canada 1984- International Society for Heart Research (American Section) 1985- International Society for Myochemistry 1988- Pharmacological Society of Canada 1988- Canadian Cardiovascular Society 1988- Western Pharmacological Society 2001 Fellow, American Heart Association, Basic Science Council

CV

2009- Obesity Society University Committees: 1990- Pediatric Cardiology Resident Training Committee 1990-1995 Chairman, Northern Alberta Institute of Technology Lab Sciences Curriculum Advisory Committee 1992-1996 Member, Health Sciences Animal Welfare Committee, Faculty of Medicine 1992 Co-chairman, U. of A. Hospitals, Strategic Planning Sub-committee on Research in Cardiac Sciences 1992-2008 Planning and Priorities Committee, Perinatal Research Centre Member, Faculties Council Library Committee Chairman, Pediatric Resident Research Committee 1998-2007 Member, Medical Sciences Graduate Program Committee 1998-2005 Graduate Student Coordinator, Department of Pediatrics 2003-2006 Member, Faculty Evaluation Committee 2004- Representative, Provost Office for Search and Selection Committee 2005-2007 Member, Research Advisory Committee, Faculty of Medicine and Dentistry 2008-2009 Member, Dean’s Search and Selection Committee, Faculty of Medicine and Dentistry 2008-2010 Member, Planning and Priorities Committee, Faculty of Medicine and Dentistry 2010- Scientific Advisory Committee, Women’s and Children’s Health Research Institute 2011-2012 Member, Faculty Research Committee 2011-2012 School Research Lead (Interim), Cardiac Sciences, Faculty of Medicine & Dentistry 2014- Interim Director (Basic Sciences), Cardiovascular Translational Sciences Institute Graduate Students Supervised: Name Degree Awarded Funding Present position Mr. Tino D. Piscione MSc Grant Pediatric Nephrologist Univ. of Toronto 1987 Hosp. for Sick Children (Co-supervised with Dr. P. Olley and Dr. F. Coceani) Dr. Stephen R. Wall PhD AHFMR Research Associate Univ. of Alberta 1988 Studentship London, Ontar Dr. Tom Broderick PhD CDA Professor Univ. of Alberta 1993 Studentship Midwestern U. AZ Dr. Maruf Saddik PhD MRC -Fellowship Pathologist, Univ. of Alberta 1993 AHFMR-Studentship Edmonton Dr. Jim Gamble PhD HSFC Research Coordinator Univ. of Alberta 1996 Studentship Baxter Laboratories Dr. Brett Schonekess PhD AHFMR Research Consultant, Univ. of Alberta 1996 Studentship Calgary, Alberta Dr. Darryl Belke PhD HSFC Associate Professor

1997 University of Calgary Dr. Olefemi Makinde PhD AHFMR Research Associate,

CV

University of Alberta 1998 Studentship Chicago Dr. Chad Lund MSc Perinatal Research Cardiologist, Ottawa University of Ottawa Dr. Liu Que PhD PhD scholarship Research Scientist, 2000 Chemtex, San Fransico Dr. Michael Steinmetz Exchange Student Medical Resident Germany 2000-2001 Dr. Laura Atkinson PhD AHFMR Studentship Research Associate,

2002 Simon Fraser University Dr. Arzu Onay PhD AHFMR Studentship Associate Professor, 2003 U. of Ankara, Turkey Dr. Emily Manning MSc Research Grant Medical Resident,

2003 Cambridge, UK Dr. Judith Altarejos PhD CIHR Studentship Asst. Professor, Burnham Institute, 2004 Orlando Dr. Teresa Hopkins PhD AHFMR Studentship Patent Law, Boston 2005 Ms. Maysa Taha MSc Research Grant Public Health Program, UofA 2007 Dr. Clifford Folmes PhD HSF/AHFMR Asst. Professor 2008 Mayo Clinic, Scottsdale, Az. Dr. John Ussher PhD AHFMR Asst. Professor University of Alberta Ms. Lene Axelson PhD Zealand Pharma Graduate Student Mr. Virgilio Cadete MSc Research Grant PhD student University of Saskatoon Ms. Anna Lam MD Graduate student Dr. Victoria Lam MD/ PhD AHFMR part time Graduate student 2011 Studentship Ms. Vaninder Sidhu MSc Motyl Studentship Graduate student 2013 Mr. Osama Abo Alrob PhD Research Grant Assistant Professor, 2014 Jordan Mr. Tariq Al-Tamini PhD Research Grant Graduate Student

CV

Ms. Natasha Fillmore PhD AIHS Studenship Graduate Student Mr. Ken Miller MSc Research Grant Graduate Student Ms. Sonia Rawat MSc Research Grant Graduate Student Ms. Kim Ho MSc Pediatrics Graduate Student Post-Doctoral Fellows Supervised: Name Period Trained Funding Present Position Dr. Rick Schulz 1991-1993 MRC / AHFMR Professor (Co-supervised with Dr. P.M. Olley) Fellowships U. of Alberta Dr. Toshiyuki Itoi 1991-1994 HSFC Professor

Post-doctoral Fellow Kyoto Prefectural University of Medicine

Dr. Z. el Alaoui Talibi 1993 Research Grant Professor, (Co-supervised with Drs. Clanachan and Schulz) Morocco Dr. Bin Liu 1994-1996 Research Grant Computer Consultant (Co-supervised with Drs. Clanachan and Schulz) Private Business Dr. Will Ford 1994-1996 Research Grant Research Associate, (Co-supervised with Drs. Clanachan and Schulz) London, UK Dr. John Gillespie 1995 Research Grant Research Technician Dundee, Scotland Dr. Naomi Kudo 1994-1995 HSFC Associate Professor Post-doctoral fellow Teikyo University Dr. Jason Dyck 1996-1999 HSFC/AHFMR Professor and Director,

Fellowship Cardiovascular Research U. of Alberta

Dr. M. Taniguchi 1996-1998 Research Grant Associate Professor,

Cardiology Jeiki University, Tokyo Dr. Paul Kantor 1996-1999 AHFMR Clinical Professor, Scholarship University of Toronto Dr. Jun Sakamoto 1997-1999 Research Grant Assistant Professor. Cardiology,Saporo

CV

Dr. Peter Brindley 1999-2000 HSFC Fellowship Associate Professor, Specialist, ICU U. of A. Hospital Dr. Fiona Campbell 1999-2002 AHFMR Fellowship Research Associate U. of Glasgow, Scotland Dr. Nanda Sambandam 2000-2003 AHFMR Fellowship Assistant Professor, Washington U., St Louis Dr. Martin Spoor 2000-2003 AHFMR Clin. Fellowship

Assistant Professor, U. of Michigan, Ann Harbour M (deceased 2008) Dr. D. Morabito 2001-2005 AHFMR/HSF Fellowship Research Associate Dr. Mohammad Askar 2003-2005 Research Grant Research Associate Dr. Anna Noga (co-sup) 2003-2007 AHFMR Fellowship Research Associate Dr. Christopher Lee 2003-2007 AHFMR Fellowship MD Dr. Nayna Manga 2005-2006 Research Grant Post-doctoral Fellow Dr. A. Palaniyapan 2005-2007 Research Grant Research Associate Dr. Wendy Keung 2006-2011 HSFC/ AHFMR Fellowship Asst. Professor, Hong Kong Dr. Wei Wang 2006 AHFMR Clinical Fellowship Post-doctoral Fellow Dr. Tatsujiro Oka 2006-2009 Research Grant Asst. Professor University of Kyoto Dr. Su Gao 2007-2010 HSFC Research Associate Dr. Lyan Zhang 2007-2011 AHFMR Research Associate Dr. Jagdip Jaswal 2008-2012 Mazankowski Alberta AIHS Heart Institute Dr. V. Samokhvalov 2008-2012 AHFMR Research Associate Dr. Alda Huqi 2010 Research Grant Asst. Professor, Cardiology

Pisa Italy

Dr. Jun Mori 2010-2013 Research Grant Asst. Professor, Kyoto University

Dr. S. Sankaralingam 2011- 2014 AIHS Asst. Professor, Qatar School of Pharmacy, Doha, Qatar Dr. Abhishek Gupta 2014-2015 Research Grant Post-doctoral Fellow Dr. Arata Fukushima 2014- Research Grant Post-doctoral Fellow

CV

Invited Lectures: 1984 Cardiovascular Research Focus, The Hospital for Sick Children 1985 Division of Pharmacology, University of British Columbia 1986 Department of Pharmacology, University of Alberta 1987 Byk Gulden Laboratories, Konstanz, West Germany 1988 Canadian Cardiovascular Society, Montreal, Quebec 1989 International Society for Heart Research, Tokyo, Japan Osaka Medical School, Osaka, Japan 1989 Kyoto Medical School, Kyoto, Japan 1989 Department of Physiology, University of Saskatchewan 1990 Nordic Laboratories, Scottsdale, Arizona 1990 Department of Pharmacology, Dalhousie University, Halifax 1991 Current Concepts in Carnitine Research, Atlanta, Georgia 1991 Third International Symposium on Lipid Metabolism in the Normoxic and Ischemic Heart,

Rotterdam, The Netherlands. 1991 Cardiovascular Research Group, University of Calgary, Calgary, AB 1991 National Association of Extrahospital Cardiologists, Rome, Italy 1992 Prassus Pharmaceuticals (Jan.), Milan, Italy 1992 Prassus Pharmaceuticals (Sept.), Milan, Italy 1992 International Workshop of Energy Production in Hypertrophied Hearts, Beaune, France 1992 Outreach 92, Terrace, B.C. 1992 Veterans Administration Hospital, Portland, Oregon 1992 Ciba-Geigy, Summit, New Jersey 1992 Cardiovascular Group, Winnipeg, Manitoba 1992 Italian Cardiology Society Meeting, Rome, Italy 1993 International Society for Heart Research, European Section, Jerusalem, Israel 1993 European Congress of Cardiology, Nice, France 1993 Canadian Federation of Biological Sciences, Windsor, Ontario 1993 British Cardiovascular Society, Edinburgh, Scotland 1994 Cardiovascular Research Group, Calgary 1994 Division of Cardiology, U. of Texas Medical School 1994 International Symposium on Heart Failure, Winnipeg 1994 International Society for Heart Research, London, Ontario 1995 European Congress of Cardiac Nephrology, Assisi, Italy 1995 Pulmonary Research Group, St. Paul's Hospital, Vancouver, B.C. 1995 Department of Physiology, University of Ottawa, Ottawa, Ont. 1995 International Society for Heart Research World CongressPrague, Czech Republic 1995 Satellite Meeting of XV ISHR, Venice, Italy 1995 Pathology Rounds, St. Paul's Hospital, Vancouver, B.C. 1996 Department of Zoology, Brigham Young University, Provo, Utah 1996 Cardiology Rounds, U. of Texas Medical School, Houston 1996 Pediatric Rounds, B.C. Children Hospital, University of British Columbia 1996 50th Anniversary Celebration of the Faculty of Pharmaceutical Sciences, UBC 1996 Cardiology Rounds, Yale University 1996 Cardiology Rounds, Riyadh Medical Centre, Saudi Arabia, Saudi Arabia 1996 International Symposia on Myocardial Energy Metabolism, Buhl, Germany 1996 International Society for Heart Research (Japan Section), Symposia on Ischemic Heart 1997 International Society for Heart Research (American Section), Vancouver, Canada, Symposia on

Adaptation of Energy Metabolism

CV

1997 International Society for Heart Research (European Section), Versailles, France, Symposia on Regulation of Energy Metabolism.

1997 Dept. of Biochemistry, Case Western Reserve University, Cleveland Ohio 1997 Cardiovascular Research Group, University of Calgary, Calgary 1997 Dept. of Emergency Medicine, Carolinas Medical Center, Charlotte NC 1997 Dept. of Physiology, Case Western University, Cleveland Ohio 1997 Canadian Cardiovascular Society, Winnipeg 1997 Department of Nutrition, University of Montreal 1998 25th Anniversary, Egyptian Society of Cardiology, Cairo, Egypt 1998 XIII World Congress of Cardiology, Rio de Janeiro, Brazil 1998 VIth Congress of Czech Society of Cardiology, Prague, Czech Republic 1998 Experimental Biology ’98, San Francisco, CA 1998 XVIth World Congress of the International Society for Heart Research, Rhodes, Greece 1998 Philippine Heart Association, Manila, Philippine 1998 Vastorel Symposium, Servier International, Beijing, China 1998 International Society for Heart Research, XX Annual Meeting of the American Section,

Ann Arbor, Michigan 1998 2nd International Congress, Polish Cardiac Society, Kotowice, Poland 1998 Novonordisck, Copenhagen, Denmark 1998 Vastarel Symposium, Paris 1998 Hormones and the Heart, Naples, Italy 1998 International Conference on Diabetes and the Heart and Vasculature, Winnipeg, Manitoba. 1999 Mechanism of action of trimetazidine. Cardiologists Symposia, Beijing, China, January 30, 1999 Altering fatty acid oxidation in the heart: A target for pharmacological

Intervention. February 25, 1999. Novartis, Newark NJ. 1999 Can one change cardiac cell metabolism? March 19, 1999, Paris, France. Societe Francaise de Cardiologie Annual Scientific Sessions. 1999 Abnormal myocardial fatty acid metabolism in the ischemic heart. March 28, 1999. Tokyo,

Japan, Circulation 9, Japan. 1999 Mechanism of action of trimetazidine. March 21, 1999, Istanbul, Turkey

3rd Academic Cardiology Colloquim. 1999 Control of fatty acid oxidation in the heart.April 13, 1999, Bristol Mayers Squibb, Princeton, NJ 1999 Treatment of ischemic heart disease. April 29, 1999, Hong Kong,

Hong Kong College of Cardiology Seminar 1999 Malonyl CoA control of fatty acid oxidation in the heart. May 6, 1999, Dallas, TX, Symposia

and Training: 13 C in metabolic research. 1999 Abnormal control of fatty acid oxidation in the diabetic rat heart. June 4, 1999, Winnipeg, MB,

International Conference on diabetes and Cardiovascular Disease 1999 Malonyl CoA control of fatty acid oxidation in the reperfused ischemic heart. August 11, 1999,

Pfizer, Groton, CT. 1999 Optimizing cardiac metabolism in ischaemic heart disease: a single explanation. August 28,

1999, Barcelona, Spain, XXIst European Congress of Cardiology. 1999 Transcriptional control of signaling molecules in fatty acid oxidation. Cardiovascular Seminars,

72nd Scientific Session of the American Heart Association, Atlanta, GA. November 7-11, 1999. 1999 Optimizing energy metabolism in the ischemic heart. December 8, 1999. Edmonton, Alberta, Cardiology Grand Rounds 2000 Metabolic agents. A new approach in treating ischaemic heart disease. The Caribbean Cardiac Society, XVth Caribbean Cardiology Conference, Paradise Island, Bahamas. July 20-23, 2000 2000 Cardiac metabolism. The Diabetic Heart. The Caribbean Cardiac Society, XVth Caribbean Cardiology Conference, Paradise Island, Bahamas. July 20-23, 2000

CV

2000 Chantilly, France, April 27-29, 2000, International Workshop on Cardiac Metabolism 2000 Lahore/Karachi/Peshwar/Faisalabhad, Pakistan, May 20-25, 2000. Cardiac Metabolism Lectures on “Protecting the ischemic heart by optimizing energy metabolism” 2000 Pharmacology Dept. Seminar, Case Western. Cleveland, Ohio, September 27. 2000 AMPK Symposium. December 3. Boston, MA. 2000 Rome, Italy, December 18, Annual Congress of the Italian Cardiology Society 2000 Conference on “Regulation of fatty acid oxidation and ketogenesis. Brighton, England, December 20. 2001 Cardiology Residents, University of Alberta, January 10. 2001 Collip Club, Faculty of Medicine, University of Alberta, February 6. 2001 Pharmacology 2001 University of British Columbia, Vancouver BC, March 26. 2001 Cardiovascular Research Group, University of Alberta, March 29. 2001 Westlink Innovations, Edmonton Alberta, April 25. 2001 National Heart Association of Malaysia, Kuala Lumpur, Malaysia, May 13. 2001 Muttart Diabetes Research and Training Centre, U. of Alberta, June 11. 2001 Satellite Meeting, XVII World Congress of the International Society of Heart Research,

Banff, Alberta. July 5. 2001 XVII World Congress of the International Society of Heart Research, Winnipeg Manitoba,

July 7. 2001 56th Congress of the Brazilian Society of Cardiology, Goianna, Brazil, October 2. 2001 Department of Pharmacology, Dalhousie University, Halifax, November 19. 2002 Pfizer, Sandwich, Kent, UK. January 9, 2002. Cardiovascular energy metabolism relevance to

ischemic heart disease. 2002 Division of Endocrinology and Metabolism, University of Pittsburgh, PA. Malonyl-CoA

control of fatty acid oxidation in the ischemic and non-ischemic heart. January 17, 2002. 2002 Division of Physical Education, University of Alberta. Cardiac adaptation (inadaptation) to

myocardial ischemia. January 22, 2002. 2002 Metabolic modulator: How to help mend a sick newborn heart. Banff, Western Perinatal

Meeting, Feb. 16, 2002. 2002 Peroxisomal proliferator activated receptor control of fatty acid oxidation in the heart. Merck

Laboratories, Ruthering NJ. Feb. 25, 2002. 2002 Metabolic Modulation in the management of coronary artery disease. Cardiology at the Limits.

Cape Town, South Africa, April 5-8, 2002 2002 Metabolic Management of Coronary Artery Disease to the Heart Failure Group, Duke Medical

School, Durham, NC. April 18, 2002 2002 Inhibiting fatty acid oxidation as a therapeutic approach to treating ischemic heart disease.

Hopitaux Universitaire de Geneve, Geneva, Switzerland. April 25, 2002. 2002 Modulating energy metabolism as an approach to treating coronary artery disease. London ON,

June 6, 2002. 2002 How does glucose metabolism affect viability studies. PET/CT Imaging Symposium, London

ON, June 7, 2002. 2002 European Association for the Study of Diabetes, Budapest, Hungary, Sept. 1-5, 2002 2002 AMPKK and AMPK control of fatty acid oxidation in the ischaemic heart. 2nd International

Symposium on AMP-activated protein kinase. Dundee, Scotland, Sept. 12-14, 2002. 2002 Etiology and mechanisms of heart failure: Genetic and environmental determinants. Canadian Cardiovascular Society, Edmonton, October 26, 2002. 2002 Frontiers of Congenital Cardiac Science, Edmonton, October 26, 2002. 2002 Mode of action of trimetazidine and other new metabolic agents in the treatment of ischemic

heart disease. Low Output Syndrome revisited, Amsterdam, The Netherlands, November 2002. 2003 Myocyte Metabolic Pathways. Cardiac Molecular Imaging Symposium, Ottawa, March 27-28. 2003 What’s going on in the cell? Cardiac Molecular Imaging Symposium, Ottawa, Mar. 28.

CV

2003 Cardiac Metabolism and metabolic consequences of ischemia cytoprotective role of preductal MR. Czech Cardiovascular Society, Prague, Czech Republic. May 14-15, 2003.

2003 PPAR control of fatty acid oxidation in the heart and its implication in cardiac ischemia. 46th Annual Meeting, Canadian Federation of Biological Societies. Ottawa, June 11-15, 2003.

2003 Role of fatty acid oxidation in cardiac dysfunction in the ischemic and failing heart. Targeting Metabolism in Cardiovascular Disease: From Gene Expression to Clinical Practice. Societ Heart and Vascular Metabolism. Freiburg, Germany, June 18-20, 2003.

2003 Optimizing energy metabolism as a novel approach to treating ischemic heart disease. 7th International Symposium on Pharmaceutical Sciences. Ankara, Turkey, June 24-27, 2003. 2003 Malonyl CoA control of fatty acid oxidation in the ischemic heart. XXV Annual Meeting of the

International Society for Heart Research (ISHR). Mystic, Connecticut, June 28-July 1, 2003. 2003 Potential benefits of promoting glucose oxidation in heart failure – Ranolazine? Heart failure

Society of America, 7th Annual Scientific Meeting. Las Vegas, Nevada, September 21-24. 2003 Alterations in fatty acid oxidation in the ischemic heart contribute to myocyte injury. 20th

Japanese Section of ISHR, Jikei, Japan. 2003 Optimizing energy metabolism as an approach to treating myocardial ischemia. Chugai

Pharmaceutical Co., Sendai, Japan, November 25th. 2004 A diagnostic model for evaluating disease and diabetes. Efficacy Models for Natural

Health Product Workshop. Banff, Feb. 9-10, 2004 2004 How do you structure your proposal? 3rd CIHR TORCH Program Workshop, Banff, Feb. 6. 2004 Role of malonyl CoA in mediating the metabolic abnormalities seen in obesity and diabetes. International Society for Heart Research, American Section 26th Annual

Meeting, Cancun, Mexico, May 2-5, 2004. 2004 National Research Forum for Young Investigators in Circulatory and Respiratory Health, Winnipeg, May 6-8, 2004. 2004 Sapporo University, Sapporo, Japan, Aug. 2004. 2004 Chair; Metabolic dysfunction in the diabetic heart. XVIII International Society for Heart

Research, Brisbane, Australia, Aug. 7-11, 2004. 2004 Inhibiting fatty acid oxidation as a novel therapeutic approach to treating ischaemic heart

disease. Satellite Meeting, XVIII International Society for Heart Research, Cape Town, South Africa, Aug. 13-16, 2004.

2004 Modulation of energy metabolism as an approach to treating heart failure. Satellite Meeting, XVIII International Society for Heart Research, Cape Town, South Africa, Aug. 13-16, 2004.

2004 Inhibition of fatty acid oxidation as a therapeutic target in ischemic heart disease and the failing heart. Society for Heart and Vascular Metabolism, Montebello, Quebec, Sept. 26.

2004 Metabolic dysregulation as cause for contractile dysfunction of the heart in obesity and diabetes: Is this a potential target for therapy? Heart Failure Society of America, Toronto, Sept. 2004

2004 Cardiac Excellence in Edmonton. Rotary Club Luncheon, Edmonton. 2004 Urban Spirits Dinner, Rotary Club, Edmonton. 2004 Regulation of glucose and fatty acid oxidation in the heart. Metabolic Alterations and

Disease: a Mitochondrial Link. University of Coimbra, Portugal, Dec. 6, 2004. 2004 AMP-activated protein kinase control of glucose and fatty acid metabolism in the

ischemic heart. Metabolic Alterations and Disease: a Mitochondrial Link. University of Coimbra, Portugal, Dec. 6, 2004.

2004 Targets for modulation of fatty acid oxidation in the heart. Metabolic Alterations and Disease: a Mitochondrial Link. University of Coimbra, Portugal, Dec. 6, 2004.

2005 Characterization of AMPK in the heart. Merck, Rahway, NJ. June 7, 2005. 2005 Metabolic therapy in diabetic stress. NATO Advances Research Workshop “Stress

Induced Biochanges in the Heart: From Genes to Bedside”. Antalya, Turkey, Feb. 2-7,

CV

2005 Malonyl CoA control of cardiac fatty acid oxidation: a therapeutic target for the treatment of myocardial ischemia and diabetes. Cardiovascular Research Institute, University of Maastricht, Maastricht, The Netherlands. March 9, 2005.

2005 Malonyl CoA decarboxylase inhibition improves cardiac insulin sensitivity. 25th European Section Meeting, Tromso, Norway, June 22-26, 2005.

2005 Role of fatty acid oxidation in modulating cardiac lipotoxicity and insulin resistance. Novartis, July 11, 2005.

2005 Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. The Failing Heart Under Stress: multifactorial Aspects of Acute and Chronic Heart failure. Amsterdam, The Netherlands, Nov. 20-22, 2005.

2005 Energizing the research environment of the Mazankowski Alberta. Heart Institute. Faculty of Medicine, University of Alberta. December 2005.

2006 Inhibiting malonyl CoA decarboxylase as an approach to treating obesity. Eli Lilly, Indianapolis. January 9, 2006.

2006 Optimizing energy metabolism as an approach to treat ischemic heart disease. Icapture, University of British Columbia, Vancouver. January 13, 2006.

2006 Cellular malonyl CoA decarboxylase inhibition as an approach to treating insulin resistance, obesity and ischemic heart disease. Merck, Newark. March 1, 2006.

2006 Inhibiting malonyl CoA decarboxylase as an approach to decreasing cardiac fatty acid oxidation: A novel approach to treat ischemic heart disease. Duluth, Minnesota. March 14, 2006.

2006 Metabolic approach to the treatment of ischemic heart disease. New imperatives in the management of cardiovascular disease: the latest evidence. Scientific Research Meeting of Servier International. March 26, 2006. Nagoya, Japan..

2006 Molecules to market to better health. 3rd Annual National Research Forum for Young Investigators in Circulatory and Respiratory Health. May-7, Winnipeg.

2006 University of Alberta Spin-off Success: Metabolic Modulators Research Limited. Metro Edmonton Health Industry Association. May 2, 2006.

2006 Tomorrow’s Research Cardiovascular Health Professionals: Mentoring the Next Generation of Health Researchers. 3rd Annual National Research Forum for Young Investigators in Circulatory and Respiratory Health. May-7, Winnipeg.

2006 Alterations in fatty acid oxidation in the failing heart. 28th International Society for Heart Research. June 13-16, Toronto.

2006 Optimizing energy metabolism to treating ischemic heart disease. Vastinan Symposia. July 8- 12, Seoul, Korea.

2006 Metabolic modulation in cardiac myocytes as a pharmacological approach to treat cardiac ischemia and heart failure. 15th World Congress of Pharmacology. June 6, Bei

2006 The key role of malonyl CoA in regulating cardiac energetics. 6th International Muscle Energetics Conference, July 22-27, Banff, Alberta.

2006 AMPK signaling during cardiac stress: potential therapeutic targets. Society for Heart and Vascular Metabolism 4th Annual Meeting. Cardiac Energy Metabolism in Heart Failure: from concepts to therapies. September 6-9, 2006, Semiahmoo, Washington. 2006 The AMPK/malonyl-CoA axis as a therapeutic target for the ailing heart. Heart Failure Society

of America 10th Annual Scientific meeting. September 10-13, 2006, Washington. 2006 Critical role of malonyl CoA in the regulation of cardiac response to stress. ACSM Conference

on Integrative Physiology of Exercise. September 27-30, 2006, Indianapolis, Indiana. 2006 Optimizing energy metabolism as a novel approach to treat ischemic heart disease and heart

failure. Global Conference on Heart Health and Disease. October 12-15, 2006, Winnipeg. 2006 Grant applications and the “Frontrunner’s Dynamic” – What will make the reviewers

labbergasted? Canadian Cardiovascular Society. October 21-25, Vancouver. 2006 Role of AMPK and malonyl CoA in hypothalamic control of obesity. 8th International

Symposium, Merck-Frosst/CIHR Research Chair in Obesity. AMP-activated protein kinase in

CV

obesity: metabolic node and beyond. November 3, Quebec. 2006 Optimizing energy metabolism as a novel approach to treat cardiac ischemia and heart failure.

Cardiac Sciences Group, Oxford University, Oxford UK. 2006 AMPK in the heart – Regulation of energy status. 197th Meeting of the Society for

Endocrinology. November 6-7, London UK. 2006 Targeting malonyl CoA decarboxylase as a treatment for both heart disease and obesity. Pfizer.

December 4, Groton, Connecticut. 2007 Increasing cardiac malonyl CoA levels protects the ischemic heart by decreasing fatty acid

oxidation. International Symposium on “Recent Advances in Cardiovascular Sciences” (RACS), February 14, New Delhi, India

2007 Increasing cardiac malonyl CoA level protect the ischemic heart by decreasing fatty acid oxidation. Heart Research 2007 (ISHR), February 17, Bikaner, Rajasthan

2007 High fat diet in mice – identification of MCD inhibitors. Pharmacology and Therapeutics Conference. March 4-6, Banff.

2007 The cardiac metabolic protection with 3 KAT inhibitor in IHD. April 18 – 21, Nusa Dua, Bali, Indonesia

2007 Obesity, the Cardiovascular System and the Brain. 2007 Western Obesity Summit, Kananaskis, May 6-8

2007 The changing scenario in chronic heart disease and its management. 20th Spring Congress of Korean Diabetes Association, Seoul, Korea May 10-12.

2007 The changing scenario in diabetic heart and its management. 20th Spring Congress of Korean Diabetes Association, Seoul, Korea, May 10-12.

2007 Metabolic dysregulation as a cause for dysfunction of the heart in diabetes and obesity: Is this a potential target for therapy? 20th Spring Congress of Korean Diabetes Association, Seoul, Korea, May 10-12.

2007 Carnitine in myocardial ischemia; experimental evidence. XIX World Congress of the ISHR, June 20-22, Padova-Abano, Italy

2007 Alterations in energy metabolism, in the ischemic and failing heart. XIX World Congress of the ISHR, June 25, Bologna, Italy

2007 Malonyl CoA Decarboxylase inhibition as an approach to treat obesity and ischemic heart disease. 2nd annual Metabolic Syndrome Oct 18-19, Boston, MA

2007 Optimizing energy metabolism as a novel approach to treat cardiac ischemia and heart failure. Canadian Cardiovascular Society Congress October 21-24, Quebec City, Quebec

2008 Inhibiting Malonyl COA Decarboxylase as an approach to limiting myocardial infarct size. Case Western Reserve University January 7, Cleveland, OH

2008 Inhibiting Malonyl-CoA Decarboxylase as an approach to treating ischemic heart disease and obesity. University of Alberta, January 16, Edmonton, Alberta

2008 Targeting fatty acid oxidation as an approach to treating ischemic heart disease and heart failure. Southern Regional Meeting February 21 -23, New Orleans, Louisiana

2008 Inhibiting Malonyl CoA Decarboxylase as a target for treating ischemic heart disease. NATO Advanced Research Workshop, May 12-16, Istanbul, Turkey.

2008 Inhibition of fatty acid oxidation as an approach to treat ischemic and failing heart. International Symposium on Myocardial Protection – From Lab to Man, May 20-21, Irbid & Amman, Jordan.

2008 Inhibition of fatty acid oxidation as an approach to treat ischemic heart disease and heart failure. Molecular Function & Imaging Symposium, June 19-20, Ottawa, Ontario.

2008 The role of AMP-Malonyl CoA Axis in mediating myocardial ischemic injury. Society for Heart and Vascular Metabolism, June 29 – July 1, Boston Massachusetts.

2008 Inhibiting malonyl CoA decarboxylase as an approach to treating ischemic heart disease. International Academy of Cardiology 14th World Congress on Heart Disease Annual Scientific Sessions, July 26-29, Toronto, Ontario

2008 Myosin light chain kinase is a novel 5’AMP activated protein kinase kinase (AMPKK) in the

CV

heart. AMPK in Sickness and Health: From Molecule to Man, August 10-15, Snekkersten, Denmark

2008 Obesity, Nutrition and Metabolism in Heart Failure. Heart Failure Society of America, September 21-24, Toronto, Ontario

2008 Targeting Malonyl CoA inhibition of mitochondrial fatty acid uptake as an approach to treat cardiac ischemia. Mitochondrial Biology in Cardiovascular Health & Disease Conference, October 6-7, Bethesda, Maryland

2009 Inhibiting fatty acid oxidation as an approach to treat ischemic heart disease and heart failure. Borun Lectureship, UCLA, January 15-16, Los Angeles, California

2009 Energy metabolic phenotype of the cardiomyocyte during development and differentiation. 6th International Ascona Workshop on Cardiomyocyte Biology. April 26, Ascona, Switzerland

2009 Pyruvate dehydrogenase kinase inhibition as an approach to treat ischemic heart disease, heart failure and diabetes. April 28, Roche, Basal, Switzerland

2009 Inhibition of malonyl CoA decarboxylase as an approach to treat ischemic heart disease. 2nd International Meeting on Myocardial Protection from Bench to Clinical Application. May 2-5, Irbid & Amman, Jordan.

2009 Cardiac energy metabolism in obesity. International Society for Heart Research (ISHR) North American Section meeting. May 26-29, Baltimore, Maryland, U.S.A.

2009 The fetal heart, the embryonic stem cell and tumorigenic cells: Cousins in phenotype of energy metabolism. University of Alberta, June 4, Edmonton, Alberta.

2009 Treating ischemic heart disease that inhibits fatty acid oxidation. July 14, Roche Nutley, New Jersey.

2009 Inhibition of malonyl CoA decarboxylase as an approach to treat heart failure and ischemic heart disease. Recent Advancement in Cardiovascular Biology and heart Failure Symposium. China, July 29- 31, Shanghai, China.

2009 Imaging of the left ventricular remodeling and function. Canadian Cardiovascular Congress, October 24, Edmonton, Alberta.

2010 Targeting Malonyl CoA as an approach to treat heart disease, obesity and diabetes. Preventative Medicine, Seminars in Lipoprotein Metabolism, Atherosclerosis & Nutrition. Columbia University, May 12, New York, NY.

2010 PGC1 and mitochondrial function in heart failure. World Congress of Cardiology Scientific Sessions, June 16-20, Beijing, China

2010 Inhibition of Malonyl CoA Decarboxylase prevents adverse cardiac remodeling post-infarction. International Academy of Cardiology, 15th World Congress on Heart Disease, July 24-27,

Vancouver, B.C. 2010 Heart Research at the Maz. A Night at the Maz Lecture Series #1, Mazankowski Alberta Heart

Institute, October 19, Edmonton, AB 2011 Treating heart failure by optimizing cardiac energy metabolism. Heart & Stroke/ Richard Lewar

Centre of Excellence Annual Cardiovascular Scientific Day, University of Toronto, April 20-21, Toronto, ON

2011 Contribution of fatty acid oxidation to lipotoxicity in the heart. Lipid Biology and Lipotoxicity, Keystone Symposium, May 16-28, Killarney, Ireland.

2011 Developing novel heart failure therapeutics. 32 International Heart Society Research – North American Section Symposia, May 22-25, Philadelphia, USA

2011 Diet and Heart Disease. Scientific Sessions, BCVS – American Heart Association, July 18-21, New Orleans, USA

2011 Early changes in cardiac mitochondrial capacity during the development of diastolic heart failure. International Academy of Cardiology, 16th World Congress on Heart Disease, Annual Scientific Sessions, July 23-26, Vancouver, BC 2011 Energy metabolism in heart failure. Ottawa Heart Institute, Sept 6-7, Ottawa, ON 2011 Decreased fatty acid oxidation on malonyl CoA decarboxylase deficient mice does

CV

not exacerbate age-induced insulin resistance. Winnipeg Heart International Conference, October 13-16, Winnipeg, MB

2011 Promoting collaborations and translational research in a heart institute. Metabolic Diseases Workshop, University of Manitoba, November 17-18, Winnipeg, MB.

2011 Targeting malonyl CoA decarboxylase to treat heart disease, obesity and diabetes. UBC Pharmaceutical Sciences and The Centre for Drug Research and Development joint seminar series. University of British Columbia, November 21, Vancouver, BC

2011 Optimizing energy metabolism as an approach to treat heart failure. Texas Heart Institute, December 15-16, Houston, Tx

2012 Role of fatty acid oxidation in cardiac dysfunction in obesity and diabetes. January 19, Salt Lake City, UT

2012 Role of fatty acid oxidation in cardiac dysfunction in obesity and diabetes. University of Washington, February 15, Seattle, WA

2012 Hearts for Hope Fundraising dinner and silent auction. The Heart and Stroke Foundation Students Association. March 15, Edmonton, AB

2012 Metabolic therapy for the treatment of heart failure: From mice to men. April 12, Alberta Heart Training Program Seminar Series, University of Alberta, Edmonton, AB

2012 Cardiac hypertrophy delays the maturation of fatty acid oxidation in the newborn heart. April 25, Ascona, Italy

2012 Metabolic modulators as a therapy for heart failure, ISHR Conference, May 24,, Banff, Alberta 2012 The contribution of altered fatty acid oxidation to heart failure development in the newborn

heart, June 25, Oxford, England 2012 The contribution of altered energy metabolism to heart disease, AIHS Workshop, July 10,

Edmonton 2012 Role of fatty acid oxidation in cardiac disease. September 7, Frontiers in Lipid Biology, Banff,

Alberta 2012 Role of altered fatty acid oxidation in contributing to lipotoxicity in obesity. October 11,

Sanford/Burnham, Orlando 2012 Treatment of heart failure by optimizing energy metabolism. October 25, Northwestern

University, Chicago 2012 Role of altered fatty acid oxidation in contributing to lipotoxicity in obesity. October 26,

Washington University of St. Louis, St.Louis Missouri 2012 Treating heart failure by optimizing energy metabolism. Cardiovascular Research Centre

Seminar Series, November 1, University of Alberta. 2012 Obesity and heart failure. American Heart Association Scientific Sessions, November 6, Los

Angelos, California 2012 Stimulating glucose oxidation as an approach to treat heart failure. Amgen talk, November 12,

San Francisco CA. 2012 Targeting malonyl CoA decarboxylase to treat heart disease. November 13, Lycera talk, Ann

Arbour. MI 2012 Coping with stress. December 6, Global TV Edmonton Interview 2013 Modulation of Malonyl-CoA and Cardiac Metabolic Consequences. Keystone Conference,

Mitochondrial, Metabolism and Myocardial Function-Basic Advances to Translational Studies. February 3, 2013. Keystone CO.

2013 Development of Cardiac Insulin Resistance in the Metabolic Syndrome , Japanese Circulation Society. March 16, 2013. Yokoyama, Japan.

2013 Angiotensin II Inhibition of Cardiac CarbohydratMetabolism Contributes to the Cardiorenal Syndrome, Japanese Circulation Society . March 17, 2013. Yokoyama, Japan.

2013 Promoting Glucose Oxidation to Treat Heart Disease and Cancer, Hatter Institute Symposia. May 3, Cape Town South Africa.

2013 Introduction to Cardiac Metabolism for the Pulmonologist. American Thoracic Society

CV

International Conference. May 19, 2013, Philadelphia, PA. 2013 Targeting Fatty Acid and Carbohydrate Oxidation in the Ischemic and Failing Heart.

ISHR XXI World Congress. July 2, 2013, San Diego CA. 2013 Enhancing Glucose Oxidation as an Approach to Treat Heart Failure. International Academy of Cardiology World Congress. July 29, 2013. Vancouver BC. 2013 A Review of Cardiac Energy Metabolism: Warburg, Randle and Krebs for the Non-Biochemist. 2013 Grover Conference. September 8, 2013, Sedalia CO. 2013 Myocardial Cytoprotection. September 27, 2013. Pecs, Hungary. 2014 The Contribution of Diabetes and Obesity to Heart Failure. Alterations in sirtuin 3 control of

fatty acid oxidation in the myocardium of obese mice. VIIth International Conference on Recent Advances in Cardiovascular Sciences (RACS). January 31, 2014. Delhi Institute of Pharmaceutical Sciences and Research, Delhi, India.

2014 Stimulating cardiac glucose oxidation as an approach to treat heart failure. February 2, 2014. India Science Congress, Jammu India.

2014 Treating heart failure by optimizing cardiac energy metabolism. Cardiovascular Research Symposium. February 9, 2014. College of Pharmacy, Qatar University.

2014 Malonyl CoA and acetyl CoA control of energy metabolism in ischaemic heart disease and heart failure. Biochemical Society Focused Meeting: Coenzyme A and its derivatives in Cellular Metabolism and Disease. March 28, 2014. Charles Darwin House, London UK.

2014 International Society for Heart Research 2014. Inhibiting fatty acid oxidation as a novel approach to treating heart failure. May 11, 2014. Miami, FA USA.

2014 CIHR Young Investigators Forum. The Entrepreneurial Scientist: Innovation, Intellectual Property and Commercialization. May 28, 2014. Edmonton AB

2014 Servier Symposia. Stable angina: the new energy target. June 19, 2014. Mexico City, Mexico. 2014 Stimulating cardiac glucose oxidation as an approach to treat heart failure in obesity.

2nd Cardiovascular Forum for Promoting Centres of Excellence and Young Investigators. September 4-6, 2014. Winnipeg, Manitoba.

2014 Stimulating glucose oxidation prevents adverse remodeling in the failing heart. September 18, 2014. Novartis, Cambridge MA.

2014 Optimizing energy metabolism as an approach to treat ischemic heart disease and heart failure. Agents of Change Research Symposium. September 26, 2014. Vancouver BC

2014 Stimulation of glucose oxidation as an approach to treat heart failure. European Section of the International Academy of Cardiovascular Sciences. October 8-11, 2014. Balatongyörök, Hungary.

2015 Protein acetylation and fatty acid oxidation. 35th International Society for Heart Research,

North American Section, Seattle WA, June 7-10, 2015. 2015 How to get the most of your mentor, Women and Children’s Health Research Institute Research

Day, University of Alberta, October 2015. 2015 Optimizing energy metabolism as an approach to treat heart failure, Rutgers University, April 2015 Energy Metabolism in the Newborn: The infant is not a small adult, Discovery Research

Rounds, Department of Pediatrics, University of Alberta, May 2015 Obesity-induced heart failure, International Academy of Cardiovascular Sciences, Omaha,

Nebraska, Oct. 2015 Alterations in cardiac energy metabolism in heart failure associated with obesity, Korean

Society of Obesity, Seoul, South Korea, November 2015 History of the Society for Heart and Metabolism, Tarrytown New York, Oct. 2015 Targeting fatty acid oxidation to treat heart failure, University of Pittsburgh, Dec 16th. 2016 Developmental changes in cardiac energy metabolism in the newborn. Pediatric Grand Rounds,

University of Alberta, Jan 21st. 2016 Optimizing Energy Metabolism as an Approach to Treat Heart Failure, University of Calgary,

Jan 28th.

CV

2016 Cardiac Metabolic Complications Associated with Diabetes, 2016 National Diabetes Forum, Mont-Tremblant, Quebec, Mar 9th.

2016 Targeting cardiac energy metabolism as a therapy to treat heart failure, 2016 ISHR World Congress, Buenos Aires, Argentina, April 21st.

2016 Cardiac energy metabolism and myocardial dysfunction: Potential new avenues for treatment of heart failure. City-wide Heart Failure Dinner Lecture Series, June 20th

2016 Glycemia Control and Heart Failure Risk: Are Alterations in Cardiac Energy Metabolism Involved? Jansen Diabetes Rounds, Edmonton, July 12th.

2016 Acetyl CoA and CoA regulation of cardiac energy metabolism in health and disease via post-translational modificatinos of mitochondrial acetylation. Coenzyme A FEBS Workshop, Marseille France, August 23rd.

2016 Insulin glarine effects on cardiac energy metabolism. ESC Congress, Rome, Aug. 30th. 2016 Role of altered cardiac branched chain amino acid catabolism in heart failure development. Am

J Physiol Symposia. Omaha, Nebraska, Sept. 8th

2016 Tips on how to write a research grant. University of Hong Kong, Hong Kong, Sept. 4th. 2016 Targeting energy metabolism to treat heart failure. University of Hong Kong, Hong Kong,

Sept. 5th

2016 Glycemia Control and Heart Failure Risk: Are Alterations in Cardiac Energy Metabolism Involved? Jansen Diabetes Rounds, Calgary, Sept. 13th.

2016 Acetylation control of cardiac fatty acid oxidation and energy metabolism in obesity and diabetes. IACS NA meeting, Sherbrooke, Quebec, Sept. 23rd.

2016 Targeting cardiac fatty acid oxidation to treat heart failure. IACS Scientific Sessions, Marseille, France. Oct. 2nd

2016 Treating heart failure by targeting cardiac energy metabolism. Duke Cardiovascular Research Group, Duke University, Raleigh NC. Nov. 9th

2016 Amino acid metabolism in heart failure. American Heart Association, New Orleans, LA. Nov. 14th

2016 Targeting myocardial energy substrate metabolism American Heart Association, New Orleans LA. Nov. 15th

2016 Optimizing cardiac energy metabolism as an approach to treat heart failure. Dean’s Research Rounds, Faculty of Pharmacy and Pharmaceutical Sciences, Edmonton, Alberta, Dec. 8th.

CV

Research Interests: My research focuses on the control of fatty acid oxidation in the heart. This includes the molecular mechanisms responsible for the rapid maturation of fatty acid oxidation in the heart following birth and the high rates of fatty acid oxidation in the myocardium of the diabetic, as well as how excess use of fatty acids by the heart contributes to ischemic heart disease. My research advances in this area in the last 5 years include: 1) Malonyl CoA control of fatty acid oxidation: A key component of my research focuses on characterizing the molecular mechanisms involved in the control of cardiac malonyl CoA, a major regulator of fatty acid oxidation in heart due to its inhibition of mitochondrial fatty acid uptake. We showed that malonyl CoA production by acetyl CoA carboxylase (ACC) is a key regulatory step in the oxidation of cardiac fatty acids, and that the heart contains an AMP-activated protein kinase (AMPK) that phosphorylate and inhibits ACC activity. AMPL acts as fuel gauge, and is activated during times of stress to increase fatty acid oxidation. We characterized two other proteins in the heart central to malonyl CoA control: 1) malonyl CoA decarboxylase (MCD), which degrades malonyl CoA and 2) AMPK kinase (AMPKK), which phosphorylates and activates AMPK. We produced a MCD adenovirus to increase MCD expression/activity in cardiac cells, and a MCD knock-out mouse, which we have used to confirm the key role of malonyl CoA as regulator of cardiac fatty acid oxidation. 2) Cardiac fatty acid oxidation rates during and following ischemia: High rates of fatty acid oxidation occur during and following cardiac ischemia (acute myocardial infarction, cardiac surgery, or angina pectoris), and contribute to ischemic injury. We have made important contributions to determining how alterations in fatty acid oxidation contribute to ischemic injury. We showed that a decrease in malonyl CoA levels during and following ischemia is an important mechanism contributing to the high rates of fatty acid oxidation. We also showed that this is due to an increase in AMPKK and AMPK, a decrease in ACC, and a high MCD activity. Our research has also determined why high rate of fatty acid oxidation decrease cardiac function and efficiency during and following ischemia. We showed that high fatty acid oxidation rates decrease cardiac function and efficiency following ischemia, due to an inhibition of glucose oxidation. This uncouples glycolysis from glucose oxidation, resulting in proton production in the critical period of reperfusion, which delays recovery of pH following ischemia. We develop methodology that has allowed us to directly measure pH in fatty acid perfused working rat hearts (using 31P-NMR techniques), while simultaneously measuring glycolysis and glucose oxidation. We have demonstrated that uncoupled glucose metabolism is an important source of acidosis in the ischemic heart, which markedly decreases cardiac efficiency. 3) Optimizing energy metabolism is a novel approach to treating ischemic heart disease: An exciting development in the last 5 years is the recognition that inhibition of fatty acid oxidation is a novel clinical approach to treating ischemic heart disease and heart failure. We have shown that a number of different approaches to inhibiting fatty acid oxidation and stimulating glucose oxidation will improve cardiac function and efficiency in the ischemic heart. We demonstrated that two existing anti-anginal drugs, trimetazidine and ranolazine, act by inhibiting fatty acid oxidation, at the level of long chain 3-ketoacyl CoA thiolase, the last enzyme involved in mitochondrial -oxidation of fatty acids. In collaboration with Chugai Pharma USA we developed inhibitors of MCD, that increase myocardial malonyl CoA levels, decreases fatty acid oxidation during and following ischemia, and improved cardiac function and efficiency during and following ischemia. This novel approach to treating myocardial ischemia will soon be undergoing clinical testing in patients with angina pectoris. 4) Maturation of fatty acid oxidation in the newborn heart: We previously showed that within days of birth myocardial fatty acid oxidation rate increases dramatically and becomes the major source of myocardial ATP production. We found that a decrease in ACC activity and malonyl CoA levels secondary of phosphorylation of ACC by AMPK is an important step in this increase in fatty acid oxidation. We have also shown that alterations in plasma insulin and adiponectin contribute to this maturation of fatty acid oxidation by altering AMPKK and AMPK activity. Recently, using heart biopsies obtained from newborns undergoing heart surgery, we also showed that the maturation of fatty acid oxidation in humans appears to be similar to the pathway(s) we

CV

characterized in the newborn rabbit heart. 5) Fatty acid oxidation in the myocardium of the diabetic: A prominent change that occurs in the hearts of diabetics is a marked reduction in glucose use, with fatty acid oxidation accounting for almost all of the myocardial oxygen consumption. A decrease in ACC activity and increase in MCD activity in the diabetic heart contributes to these high fatty acid oxidation rates. We demonstrated that increased in peroxisomal proliferators activated receptor (PPAR) has a key role mediating the high rates of fatty acid oxidation in the diabetic heart. At the level of the heart, activation of PPAR actually increases fatty acid oxidation and can contribute to the high fatty acid oxidation rates seen in the diabetic.

CV

PATENTS: TITLE - Post-surgical treatment with dichloroacetate 1. United States Patent #6,727,284, Issued April 27, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai, Koon Teo and Jason Dyck 2. Canada Patent Application #2,305,183, Issued September 23, 1998 Inventors: Gary Lopaschuk, Ruth Collins-Nakai, Koon Teo and Jason Dyck 3. Japan Patent Application #2000-514634, Filed September 30, 1998 Inventors: Gary Lopaschuk, Ruth Collins-Nakai, Koon Teo and Jason Dyck TITLE - Methods of Cardioprotection Using Dichloroacetate in Combination with an

Inotrope 4. United States Patent #6,693,133, Issued February 17, 2004 Inventors: Gary Lopaschuk and Ruth Collins-Nakai 5. Australia Patent Application #2004315552, Filed January 16, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai 6. China Patent Application #200480042494.4, Filed January 16, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai 7. Europe Patent Application, #2006-548415 , Filed Jan. 16, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai 8. Japan Patent Application #2006-548415, Filed January 16, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai 9. United States Patent #7,432,247, Issued October 7, 2008 Inventors: Gary Lopaschuk, Ruth Collins-Nakai 10. Canada Patent Application #2489853, Filed January 16, 2004 Inventors: Gary Lopaschuk, Ruth Collins-Nakai TITLE - Dichloracetate in combination with cardioprotective or hemodynamic drugs 11. United States Patent Application #11/339988, Filed June 7, 2006, Inventor: Gary Lopaschuk 12. Australia Patent Application #2003278896, Filed June 20, 2003, Inventor: Gary Lopaschuk 13. Canada Patent Application #2490636, Filed June 20, 2003, Inventor: Gary Lopaschuk 14. Japan Patent Application #2004-514473, Filed June 20, 2003, Inventor: Gary Lopaschuk 15. Europe Patent # 1517705, Issued May 21, 2008, Inventor: Gary Lopaschuk 16. Germany Patent # 1517705DE, Issued May 21, 2008, Inventor: Gary Lopaschuk 17. Spain Patent # 1517705ES, Issued May 21, 2008, Inventor: Gary Lopaschuk 18. France Patent # 1517705FR, Issued May 21, 2008, Inventor: Gary Lopaschuk 19. Ireland Patent # 1517705IE, Issued May 21, 2008, Inventor: Gary Lopaschuk 20. Italy Patent # 1517705IT, Issued May 21, 2008, Inventor: Gary Lopaschuk 21. United Kingdom Patent # 1517705UK, Issued May 21, 2008, Inventor: Gary Lopaschuk 22. PCT/CA03/00929 Patent Application, Filed June 20, 2003, Inventor: Gary Lopaschuk TITLE – Compounds that stimulate glucose utilization and methods of use 23. United States Patent #7,084,173, Issued August 1, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 24. United States Patent #7,074,828 B2, Issued August 1, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 25. United States Patent #7,074,828 B1, Issued July 11, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 26. United States Patent Application #11/064,713, Issued April 28, 2009 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 27. PCT/1B06/001587 Based on US 11/064,713, Filed February 23, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck

CV

28. United States Patent Application #11/369,182, Issued January 6, 2009 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 29. Canada Patent Application #2,480,557, Filed March 31, 2003 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 30. Japan Patent Application #2003-580,269, Filed March 31, 2003 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 31. Europe Patent Application #03,745,384.2, Filed March 31, 2003 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 32. Europe Patent Application #06765523.3, Filed February 23, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 33. Hong Kong Patent Application #08105963.4, Filed May 28, 2008 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 34. Korean Patent Application #10-2007-702151, Filed February 23, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 35. United States Patent Application #12/403,143, Filed March 12, 2009 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 36. Australia Patent Application #2006242936, Filed February 23, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 37. Canada Patent Application #200680008419.5 Filed Septenber 14, 2007 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck 38. United States Patent Application #60/368,536, Filed April 1, 2006 Inventors: Gary Lopaschuk, John Vederas, Jason Dyck TITLE – Methods for the treatment of diseases using malonyl-CoA decarboxylase inhibitors 39. European Patent Convention Patent #1353662, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 40. Germany Patent #1353663/DE60219595.0, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 41. Spain Patent #1353663, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 42. France Patent #1353663, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 43. Great Britain Patent #1353663, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 44. Italy Patent #1353663, Issued April 18, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 45. Japan Patent #4503232, Issued January 30, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 46. United States Patent #7,385,063, Issued June 10, 2008. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk 47. United States Application #10/468,378, Filed June 10, 2008. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk TITLE – Malonyl-CoA decarboxylase inhibitors useful as metabolic modulators 48. European Patent Convention Patent #1377290, Issued October 4, 2006. . Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 49. Spain Patent #1377290, Issued January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 50. Japan Application #2009-261692, Filed January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 51. United States Application # 7,279,477, Issued October 9, 2007. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk

CV

52. Australia Patent #2002245924, Issued January 6, 2006. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 53. Canada Application #2435067, Filed January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 54. Canada Application #2735478, Filed January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 55. Canada Application #2735267, Filed January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 56. China Patent #ZL02803537.2.2, Issued August 19, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 57. China Patent #ZL02803537.2.2, Issued August 19, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 58. China Application #200910139558.7, Filed January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 59. European Patent Convention Application #1411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 60. Spain Patent #1411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 61. France Patent #411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 62. Italy Patent #1411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 63. Hong Kong Patent #1068285B, Issued January 14, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 64. Hong Kong Patent #10105316.4, Issued January 26, 2005. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 65. United Kingdom Patent #1411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 66. Germany Patent #1411929, Issued May 5, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 67. United States Patent #7,524,969, Issued April 28, 2009. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk 68. United States Application #12/431,720, Filed July 21, 2003. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk 69. South Korea Patent #637564, Issued October 16, 2006. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk 70. Great Britain Patent #1377290. Issued January 22, 2002. . Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 71. France Patent #1377290. Issued January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 72. Italy Patent #1377290. Issued January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 73. Germany Patent #1377290/DE60215139.2, Issued January 22, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk TITLE – Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators 74. Australia Patent #2002251987, Issued June 2, 2005 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 75. Brazil Application #PI0207408-7, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 76. Canada Patent #2,437,409, Issued October 19, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk

CV

77. China Patent #ZL02805216.1, Issued April 23, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 78. European Patent Convention Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 79. Albania Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 80. Austria Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 81. Belgium Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 82. Switzerland Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 83. Cyprus Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 84 Germany Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 85. Denmark Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 86. Spain Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 87. Finland Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 88. France Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 89. United Kingdom Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 90. Greece Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 91. Ireland Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 92. Italy Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 93. Liechtenstein Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 94. Luxembourg Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 95. Monaco Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 96. Netherlands Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 97. Portugal Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 98. Sweden Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 99. Turkey Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 100. Lithuania Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 101. Latvia Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 102. Macedonia Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk

CV

103. Romania Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 104. Slovenia Patent #1370260, Issued November 24, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 105. Hong Kong Patent #1062633, Issued January 28, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 106. Hungary Application #P0303272, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 107. Israel Application #156827, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 108. Japan Patent #4,155,351, Issued July 18, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 109. South Korea Patent #659427, Issued December 12, 2006. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 110. Mexico Application #PA/A/2003/007441, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 111. Norway Application #2003 3665, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 112. New Zealand Patent #526883, Issued March 9, 2006.. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 113. Poland Application #204456, Issued February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 114. Russian Federation Application #2003 128307, Filed February 19, 2002. Issued. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 115. United States Patent #7,709,510, Issued May 4, 2010. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk 116. United States Application #12/772,552, Filed May 3, 2010. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk TITLE – Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors 117. United States Patent #7,696,365, , Issued April 13, 2010. Inventors: Jei-Fei Cheng et al. including Gary Lopaschuk 118. Canada Application #2533747, Filed July 28, 2004. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 119. Europe Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 120. Germany Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 121. France Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 122. United Kingdom Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 123. Spain Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 124. Italy Patent #1653944, Issued November 11, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 125. Japan Patent #4727578, Issued April 22, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk TITLE – Piperidine compounds useful as malonyl-CoA decaroxylase inhibitors 126. United States Patent #7,449,482, Issued November 11, 2008.

Inventors: Seraguniv et al. including Gary Lopaschuk

CV

127. United States Application #12/245,558, Filed October 3, 2008. Inventors: Seraguniv et al. including Gary Lopaschuk

128. Canada Application #2533749, Filed July 28, 2004. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 129. Europe Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 130. Germany Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 131. Spain Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 132. France Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 133. Great Britain Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 134. Italy Patent #1653957, Issued July 9, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 135. Japan Patent #4648317, Issued December 17, 2010. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk

TITLE – Cyanoguanidine-based azole compounds useful as malonyl-CoA decarboxylase inhibitors 136. United States Patent #7,786,145. Issued August 31, 2010. Inventors: Jie-Fei Cheng et al. including Gary Lopaschuk 137. Canada Application #2533881, Filed July 28, 2004. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 138. Europe Patent #1658071, Issued September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 139. Germany Patent #1658071, Issued September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 140. Spain Patent #1658071, Issued September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 141. France Patent #1658071, Issued September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 142. Great Britain Patent #1658071, Issued September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 143. Italy Patent #1658071, Issued July 28, 2007. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 144. Europe Application #08163168.1, Filed September 10, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 145. Japan Application #2006-522615, Filed July 28, 2004. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk TITLE – Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors 146. United States Patent #7,285,562, Filed October 23, 2007. Inventors: Mark D. Kafka et al. including Gary Lopaschuk 147. Canada Application #2533763, Filed July 28, 2004. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 148. United States Patent #7,897,615, Filed March 1, 2011. Inventors: Mark D. Kafka et al. including Gary Lopaschuk 149. Europe Patent #1648564, Issued October 17, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 150. Germany Patent #1648564, Issued October 17, 2007

CV

Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 151. Spain Patent #1648564, Issued October 17, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 152. France Patent #1648564, Issued October 17, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 153. United Kingdom Patent #1648564, Issued October 17, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 154. Italy Patent #1648564, Issued October 17, 2007 Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 155. Japan Patent #2006-522611, Filed April 22, 2011. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk TITLE – Methods for measuring the metabolism of and screening for drugs in isolated hearts 156. United States Patent #6,653,090, Issued November 25, 2003 Inventor: Gary Lopaschuk TITLE – Methods for the treatment of metabolic diseases using malonyl-CoA decarboxylase inhibitors 157. Japan Patent #4,155,361, Issued July 18, 2008. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 158. European Patent #1379243, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 159. Germany Patent #1379243/ DE60233650.3, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 160. United Kingdom Patent #1379243, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 161. France Patent #1379243, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 162. Spain Patent #1379243, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 163. Italy Patent #1379243, Issued September 9, 2009. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 164. Japan Application #2007-318038, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 165. Japan Application #2007-324412, Filed February 19, 2002. Inventors: Chugai Seiyaku Kabushiki Kaisha including Gary Lopaschuk 166. United States Patent #7,723,366, Issued May 25, 2010. Inventors: Thomas Arrhenius et al. including Gary Lopaschuk

CV

BIBLIOGRAPHY 1. Bellward GD, Li M, Lopaschuk GD, and Warren P. The effect of alpha-1-acetylmethadol hydrochloride on rat hepatic acyl hydrocarbon hydroxylase and epoxide hydrase. Res Commun Chem Path Pharmacol 2005;18:415-422 2. Lopaschuk GD, Richter B, and Katz S. Characterization of calmodulin effects on calcium transport in

cardiac microsomes enriched in sarcoplasmic reticulum. Biochemistry 1980;19:5603-5607. 3. Graf E, Verma AK, Gorski JP, Lopaschuk GD, Niggli, V Zurini, M Carafoli E, and Penniston JT.

Molecular properties of the Calcium-pumping from human erythrocytes. Biochemistry 1980;21:4511-4516.

4. Lopaschuk GD, Katz S, and McNeill JH. The effect of alloxan and streptozotocin-induced diabetes on

calcium transport in rat cardiac sarcoplasmic reticulum. The possible involvement of long chain acylcarnitines. Can J Physiol Pharmacol 1983;61:439-448

5. Lopaschuk GD, Tahiliani A, and McNeill JH. Continuous long term insulin delivery in diabetic rats

utilizing implanted osmotic minipumps. J Pharmacol Methods 1983;9:71-75 6. Rodgers RL, Lopaschuk GD, and McNeill JH. Effect of reserpine pretreatment on calcium and Ca++-

Mg++ adenosine triphosphatase activity of guinea-pig cardiac microsomes. J Pharmacol Exper Ther 1983;226:206-210.

7. Lopaschuk GD, Eibschutz B, Katz S, and McNeill JH. Depression of calcium transport in sarcoplasmic

reticulum from diabetic rats: Lack of involvement by specific regulatory mediators. Gen Pharmacol 1984;15:1-5.

8. Lopaschuk GD, Tahiliani AG, Vadlamudi RVSV, Katz S, and McNeill JH. Cardiac sarcoplasmic

reticulum function on insulin- or carnitine-treated diabetic rats. Am J Physiol 1983;245:H969-H976 . 9. Lopaschuk GD, Katz S, and McNeill JH. Characterization of cardiac microsomal sarcoplasmic

reticulum prepared from control and diabetic rats. J Pharmacol Methods 1983;10:199-206. 10. Eibschutz B, Wong APG, Lopaschuk GD, and Katz S. The presence and binding characterization of

calmodulin in microsomal preparations enriched in sarcoplasmic reticulum from skeletal muscle. Cell Calcium 1984;5:391-400.

11. Eibschutz B, Lopaschuk GD, Katz S, and McNeill JH. Ca2+-transport in skeletal muscle sarcoplasmic

reticulum of chronically diabetic rats. Res Commun Chem Pathol Pharmacol 1984;45:301-304. 12. Tahiliani AG, Lopaschuk GD, and McNeill JH. Effect of insulin treatment on long term diabetes-induced

alterations of myocardial function. Gen Pharmacol 1984;15:545-548. 13. Godin DV, Lopaschuk GD, and McNeill JH. Subcellular myocardial abnormalities in experimental

diabetes: Role of long chain acylcarnitines. Can J Cardiol 1986;2:222-229. 14. Lopaschuk GD, Hansen CA, and Neely JR. Fatty acid metabolism in hearts containing elevated levels of

coenzyme A Am J Physiol 1986;250: H351-H359. 15. Lopaschuk GD, and Neely JR. Stimulation of myocardial coenzyme A degradation by fatty acids. Am. J.

CV

Physiol. 1987;253:H41-H46. 16. Lopaschuk GD, and Neely JR. Coenzyme A degradation in the heart: effect of diabetes and insulin. J.

Mol Cell Cardiol 1987;19:281-287. 17. Lopaschuk GD, Michalak M, and Tsang H. Regulation of pantothenic acid transport in the heart.

Involvement of a Na+-cotransport system. J Biol Chem 1987;262:3615-3619. 18. Lopaschuk GD, and Tsang H. Metabolism of palmitate in isolated working hearts from spontaneously

diabetic "BB" Wistar rats. Circ. Res. 1987;61:853-858 . 19. Lopaschuk GD. Insulin effects on pantothenic acid uptake in isolated perfused working hearts from

diabetic rats. Diabetes 1988;37:1335-1338. 20. Lopaschuk GD, Wall SR, Olley PM, and Davies NJ. Etomoxir, a carnitine palmitoyltransferase I

inhibitor, protects hearts from fatty acid induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988;63:1036-1043.

21. Lopaschuk GD, and Spafford M. Response of isolated working hearts to fatty acids and carnitine

palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res 1989;65:378-387.

22. Lopaschuk GD, Michalak M, Wandler EL, Lerner RW, Piscione TD, Coceani F. and Olley, P.M.

Prostaglandin E. receptor in cardiac sarcolemma. Identification and coupling to adenylate cyclase. Circ Res 1989;65:538-545.

23. Wall SR, and Lopaschuk GD. Glucose oxidation rates in fatty acid perfused isolated working hearts from

diabetic rats. Biochim Biophys Acta 1989;1006:97-103. 24. Lopaschuk GD, McNeil J. and McVeigh J. Glucose oxidation is stimulated in reperfused hearts with the

carnitine palmitoyltransferase 1 inhibitor, Etomoxir. Mol. Cell Biochem 1989;88:175-179. 25. Lopaschuk GD. Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the

diabetic. Can J Cardiol 1989;5:315-320. 26. Lopaschuk GD, Spafford, M Davies NJ, and Wall SR. Glucose and palmitate oxidation in isolated

working rat hearts reperfused following a period of transient global ischemia. Circ Res 1990;66:546-553. 27. Lopaschuk GD. Acute insulin withdrawal contributes to ischemic heart failure in spontaneously diabetic

BB Wistar rats. Can J Physiol Pharmacol 1990;68:462-466. 28. Lopaschuk GD. and Spafford M. Energy substrate utilization by isolated working hearts of newborn

rabbits. Am J Physiol 1990;258:H1274-H1280. 29. Montague TJ, Lopaschuk GD, and Davies NJ. Viral heart disease. Chest 1900;98:190-199 . 30. McVeigh J, and Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves mechanical

recovery of ischemic rat hearts. Am J Physiol 1990;259:H1079-H1085. 31. Michalak M, Wandler EL, Strynadka K, Lopaschuk GD, Njue WM, Liu HJ and Olley. P.M. Prostaglandin

Receptor in the Heart. I. Identification and Photolabelling of the PGE2 receptor. FEBS Letters 1990;265:117-120.

CV

32. Lerner RW, Lopaschuk GD, and Olley PM. High affinity Prostaglandin E receptors in attenuate adenylyl

cyclase activity in isolated bovine myometrial membrane. Can J Physiol Pharmacol 1900;68:1574-1580. 33. Wong R, Davies N, Marshall D, Allen P, Zhu G, Lopaschuk G, and Montague T. Metabolism of normal

skeletal muscle during dynamic exercise to clinical fatiguè in vivo assessment by nuclear magnetic resonance spectroscopy. Can J Cardiol 1990;6:391-395.

34. Davies NJ, McVeigh JJ, and Lopaschuk GD. Effect of TA-3090, a new calcium channel blocker, on

myocardial substrate utilization in ischemic and non-ischemic isolated working fatty acid perfused rat hearts. Circ Res 1991;68:807-817.

35. Lopaschuk GD, and Russell JR. Myocardial function and energy substrate metabolism in the insulin-

resistant JCR:LA-corpulent rat. J Appl Physiol 1991;71:1302-1308 . 36. Saddik M, and Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate

utilization in isolated working rat hearts. J Biol Chem 1991;266:8162-8170 . 37. Nicholl TA, and Lopaschuk GD, and McNeill JH. Effects of free fatty acids and dichloroacetate on the

isolated working diabetic rat heart. Am J Physiol 1991;261:H1053-H1059. 38. Saddik M, and Lopaschuk GD. The fate of arachidonic acid and linoleic acid in isolated working rat

hearts containing normal or elevated levels of coenzyme A. Biochim Biophys Acta 1991;1086:217-224. 39. Lopaschuk GD, Spafford MA, and Marsh DR, Glycolysis is predominant source of myocardial ATP

production immediately after birth. Am. J. Physiol 1991;261:H1698-H1705. 40. Broderick TL, Barr RL, Quinney A, and Lopaschuk GD. Acute insulin withdrawal from diabetic "BB"

rats decreases myocardial glycolysis during low flow ischemia. Metabolism 1992;41:332-338. 41. Lerner R, Lopaschuk GD, and Olley PM. Prostaglandin E2 receptors in the heart are coupled to inhibition

of adenylyl cyclase via a pertussis toxin-sensitive G protein. Can J Physiol Pharmacol 1992;70:77-84. 42. Broderick T, Quinney A, and Lopaschuk GD. Carnitine stimulated glucose oxidation in isolated working

hearts perfused with high concentrations of fatty acids. J Biol Chem 1992;267:3758-3763 . 43. Finegan BA, Clanachan, AS, Coulson CS, and Lopaschuk GD. Adenosine modification of energy

substrate in use is isolated heart perfused with fatty acids. Am J Physiol 1992;262:H1501-H1506.

44. Saddik M and Lopaschuk GD. Myocardial triglycerides turnover during reperfusion of isolated rat hearts subjected to a transient period of global ischemia. J Biol Chem 1992;267:3825-3831.

45. Lerner RW, Lopaschuk GD, Catena RC, and Olley PM. Prostacyclin and prostaglandin E2 compete for

the same receptor site on cardiac sarcolemmal membranes. Biochim Biophys Acta 1992;1105:189-192. 46. Davies NJ, Lovlin R, and Lopaschuk GD. Effects of exogenous fatty acids on reperfusion arrythmias in

isolated working perfused hearts. Am J Physiol 1992;262:H1796-H1801 . 47. Lopaschuk GD, Barr R, and Wambolt R. Effects of diltiazem on glycolysis and oxidative metabolism in

the ischemic and ischemic/reperfused heart. J Pharmacol Exp Therap 1992;260:1220-1228. 48. Davies NJ, Schulz R, Olley PM, Strynadka K, Panas DL, and Lopaschuk GD. Lysoplasmenyl-

CV

ethanolamine accumulation in ischemic reperfused isolated fatty acid perfused hearts. Circ Res 1992;70:1161-1168.

49. Lopaschuk GD, Saddik M, Barr R, Huang L, Barker CC, and Muzyka RA. Effects of high levels of fatty

acids on functional recovery of ischemic hearts from diabetic rats. Am J Physiol 263: 1992;E1046-E1053.

50. Lopaschuk GD, and Spafford MA. Differences in myocardial ischemic tolerance between one and seven

day old rabbits. Can J Physiol Pharmacol 1992;70:1315-1323. 51. Dyck JRB, Lopaschuk GD, and Fliegel L, Identification of a small Na+-H+ exchanger-like message in the

rabbit myocardium. FEBS Letters 1992;310:255-259. 52. Lakey JRT, Thomson ABR, Keelan M, Lopaschuk GD, Clandinin MT, Cheeseman CI and Rajotte RV.

Dietary lipid content influences the clinical and intestinal adaptive responses to islet transplantation in diabetic rats. Diabetes Res. 1992;19:149-164

53. Wong R, Lopaschuk GD, Zhu G, Walker D, Catellier D, Burton D, Teo K, Collins-Nakai R, and

Montague, T. Skeletal muscle metabolism in the chronic fatigue syndrome in vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 1992;102:1716-1722.

54. Wong R, Lopaschuk GD, Teo T, Walker D, Catellier D, Zhu G, Burton D, Collins-Nakai R and Montague

T. In vivo skeletal muscle metabolism during dynamic exercise and recovery: Assessment by nuclear magnetic resonance spectroscopy. Can J Cardiol 1992;8:819-824 .

55. Finegan BA, Lopaschuk GD, Coulson CS and Clanachan AS. Adenosine alters glucose use during

ischemia and reperfusion in isolated rat hearts. Circulation 1993;87:900-908 . 56. Lopaschuk GD, Wambolt RB and Barr RL. An imbalance between glycolysis and glucose oxidation is a

possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Therap 1993;264:135-144.

57. Broderick T, Quinney A, and Lopaschuk GD. Beneficial effects of carnitine on mechanical recovery of

rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation 1993;87:972-981.

58. Mao GD, Thomas PD, Lopaschuk GD and Poznansky M. Superoxide dismutase (SOD)-catalase

conjugates: Role of hydrogen peroxide and the Fentin reaction in SOD toxicity. J Biol Chem 1993;268:416-420.

59. Schulz R, Strynadka KD, Panas DL, Olley PM, and Lopaschuk GD. Analysis of myocardial plasmalogen

and diacyl-phospholipids and their arachidonic acid content using high performance liquid chromatography. Anal Biochem 1993;213:140-146.

60. Itoi T, Huang L and Lopaschuk GD. Glucose use in neonatal rabbit hearts reperfused after global

ischemia. Am J Physiol 1993;34:H427-H433. 61. Gamble J, and Lopaschuk GD. Glycolysis and glucose oxidation during reperfusion of ischemic hearts

from diabetic rat hearts. Biochim Biophys Acta 1993;1225:191-199. 62. Itoi T, and Lopaschuk GD. The contribution of glycolysis, glucose oxidation, lactate oxidation and fatty

acid oxidation to ATP production in isolated bi-ventricular working hearts from 2-week old rabbits. Ped

CV

Res 34:1994;735-741 . 63. Lopaschuk GD, Lakey JRT, Wambolt R, Thomson ABR, Clandinin MT, and Rajotte RV. Islet

transplantation improves glucose oxidation and mechanical function in diabetic rat hearts. Can J Physiol Pharmacol 1994;896-903.

64. Saddik M, Gamble J, Witters LA and Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid

oxidation in the heart. J Biol Chem 1994;268:25836-25845. 65. Lopaschuk GD, Collins-Nakai, R Olley, PM Montague, TJ McNeil, G Gayle, M Ryan, T Penkoske, P

Yeung L and Finegan BA. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 1994;128:61-67.

66. Liu B, Lopaschuk GD and Wang LCH. Improved rat heart function after low Ca2+ perfused preservation

at 5oC for 18 hours. Cryobiology 1994;31:254-262. 67. Glatz JFC, Van Breda E, Keizer HA, De Jong YF, Lakey JRT, Rajotte RV, Thompson A, Van Der Vusse

GJ and Lopaschuk GD. Rat heart fatty acid-binding protein content is increased in experimental diabetes. Biochim Biophys Res Comm 1994;199:639-646.

68. Collins-Nakai RL, Noseworthy D, and Lopaschuk GD. Epinephrine increases ATP production in hearts

by preferentially increasing glucose metabolism. Am J Physiol 1994;267: H1862-H1871. 69. Saddik M, and Lopachuk GD. Triacyglycerol turnover in isolated working hearts of acutely diabetic rats.

Can J Physiol Pharmacol 1994;72:1110-1119. 70. Allard MF, Schönekess BO, Henning SL, English DR, and Lopaschuk GD. The contribution of oxidative

metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 1994; 267:H742-H750.

71. Lopaschuk GD, Belke DB, Gamble J, Itoi T and Schönekes BO. Regulation of fatty acid oxidation in the

mammalian heart in health and disease. Biochim Biophys Acta 1994;1213:263-276. 72. Lopaschuk GD and Gamble J. Acetyl-CoA carboxylase: An important regulator of fatty acid oxidation in

the heart. Can J Physiol Pharmacol 1994;72:1101-1109.

73. Montague T, De Almeida J, Lopaschuk GD, Witkowski F, Walker D, Ackman M, Davies, N Dzavik V, and Teo K. Enhanced glucose oxidation in acute low-flow myocardial ischemia: in vivo assessment by exercise body surface potential mapping. Can J Cardiol 1994;10:913-919.

74. Lopaschuk GD, Witters LA, Itoi T, Barr R, and Barr A. Acetyl CoA carboxylase involvement in the rapid

maturation of fatty acid oxidation in the newborn rabbit heart. J Biol Chem 1994;269:25871-25878. 75. Schulz R, Panas DL, Catena R, Moncada S, P Olley PM and Lopaschuk GD. The role of nitric oxide in

cardiac depression induced by interleukin-1b and tumour necrosis factor-a. Br J Pharmacol. 1995;114:27-34.

76. Broderick TL, Quinney HA, and Lopaschuk GD. L-carnitinè increases glucose metabolism and

mechanical function following ischemic in diabetic rats. Cardiovasc Res 1995;29:373-378. 77. Schönekess BO, Allard MF, Lopaschuk GD. Propionyl L-carnitine improvement of hypertrophied heart

function is accompanied by an increase in carbohydrate oxidation. Circ Res 1995;77:726-734 .

CV

78. Kudo N, Barr AJ, Barr RL, Desai S and Lopaschuk GD. High rates of fatty acid oxidation during

reperfusion of ischemic hearts are associated with a decrease in malonyl CoA levels due to an increase in 5'AMP-activated protein kinase inhibition of acetyl CoA carboxylase. J Biol Chem 1995;270:17513-17520.

79. Schönekess BO, Allard MF and Lopaschuk GD. Propionyl-L-carnitine improvement of hypertrophied rat

heart function is associated with an increase in cardiac efficiency. Eur J Pharmacol 1995;286:155-166. 80. Schönekess B, Brindley PG, Lopaschuk GD. Calcium regulation of glycolysis, glucose oxidation, and

fatty acid oxidation in the aerobic and ischemic heart. Can J Physiol Pharmacol 1995;73:1632-1640. 81. Finegan BA, Lopaschuk GD, Gandhi M and Clanachan AS. Ischemic preconditioning inhibits glycolysis

and proton production in isolated working rat hearts. Am J Physiol 1995;269:H1767-H1774. 82. Broderick TL, Panagakis G, Gamble J, Lopaschuk GD, Shug AL and Paulson DJ. L-carnitine

improvement of cardiac function is associated with a stimulation in glucose but not fatty acid metabolism in carnitine-deficient hearts. Cardiovasc Res 1995;30:815-820.

83. McCormack JG, Barr RL and Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic,

ischemic and reperfused ischemic rat hearts. Circulation 1996;93:135-142. 84. Liu B, El-Alaoui Talibi Z, Clanachan AS, Schulz R and Lopaschuk GD. Uncoupling of contractile

function from mitochondrial tricarboxylic acid cycle activity and oxygen consumption during reperfusion of ischemic rat hearts. Am J Physiol 1996;270:H72-H80

85. Henning S, Wambolt R, Schönekess B, Lopaschuk G, Allard M. Contribution of glycogen to aerobic

myocardial glucose utilization. Circulation 1996;93:1549-1555. 86. Schönekess B, Allard MF, Lopaschuk GD. Recovery of glycolysis and oxidative metabolism during post-

ischemic reperfusion of hypertrophied rat hearts. Am J Physiol 1996;271:H798-H805 87. Odland LM, Heigenhauser GJF, Lopaschuk GD, Spriet LL. Human skeletal muscle malonyl-CoA at rest

and during prolonged submaximal exercise. Am J Physiol 1996;270:E541-E544. 88. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, Lopaschuk GD. Characterization

of 5'AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996;130:67-75.

89. Hall JL, Stanley WC, Lopaschuk GD, Wisneski JA, Pizzuro RD, Hamilton CD, McCormack JG. Impaired pyruvate oxidation but normal glucose uptake in diabetic pig heart during dobutamine-induced work. Am J Physiol 1996;271: H2320-H329.

90. McCormack JG, Baracos VE, Barr R and Lopaschuk GD. Effects of ranolazine on oxidative substrate

preference in epitrochlearis muscle. J Appl Physiol 1996;81:905-910. 91. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved following ischemia by

altering both the source and fate of protons. Circ Res 1996;79:940-948. 92. Olley PM, Kasserra J, Kozak R, Lopaschuk GD. Synergism between prostaglandin E2 and isoproterenol

in stimulating glucose oxidation in the heart. Can. J Physiol Pharmacol 1996;74:590-597.

CV

93. Itoi T and Lopaschuk GD. Calcium improves mechanical function and carbohydrate metabolism following ischemia in isolated bi-ventricular working hearts from immature rabbits. J Mol Cell Cardiol 1996;28:1501-1514.

94. Hall JL, Lopaschuk GD, Barr A, Bringas J, Pizzuro RD, Stanley WC. Increased cardiac fatty acid uptake

with dobutamine infusion in swine is accompanied by a adecrease in malonyl CoA levels. Cardiovasc Res 1996;32:879-885.

95. Finegan B, Lopaschuk GD, Ghandi M and Clanachan AS. Inhibition of glycolysis and enhanced

mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischaemia. Br J Pharmacol 1996;118:2355-363.

96. Sidossis LR, Lopaschuk GD, Wolfe RR. Glucose plus insulin regulate fat oxidation by controlling the rate

of fatty acid entry into the mitochondria. J Clin Invest 1996;98:224-2250. 97. Finegan B, Ghandi M, Clanachan AS and Lopaschuk GD. Antecedent ischemia reverses adenosine on

glycolysis and mechanical function of working rat hearts. Am J Physiol 1996;271:H2116-H2125. 98. Lopaschuk GD and Stanley WC. Glucose metabolism in the ischemic heart Circulation 1997;95:313-315. 99. Schönekess BO, Allard MF, Henning SL, Wambolt RB and Lopaschuk GD. Contribution of glycogen and

exogenous glucose to glucose metabolism during ischemia in the hypertrophied rat heart. Circ Res 1997;81: 540-549.

100. Schulz R, Dodge KL, Lopaschuk GD and Clanachan AS. Peroxynitrite impairs cardiac contractile

function by decreasing cardiac efficiency. Am J Physiol 1997;272: H1212-H1219.

101. Makinde AO, Gamble J and Lopaschuk GD. Upregulation of 5’AMP-activated protein kinase is responsible for the increase in myocardial fatty acid oxidation rates following birth in the newborn rabbit. Circ Res 1997;80: 482-489.

102. Belke D, Wang L and Lopaschuk GD. Effects of hypothermia on energy metabolism in rat and Richardson’s ground squirrel hearts. J Appl Physiol 1997;82: 1210-1218.

103. Stanley WC, Lopaschuk GD, Hall JL and McCormack JG. Regulation of myocardial carbohydrate

metabolism under normal and ischaemic conditions: Potential for pharmacological interventions. Cardiovasc Res 1997;33: 243-257.

104. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR and Lopaschuk GD. Glycogen

metabolism in the aerobic hypertrophied rat heart. Circulation 1997;96: 676-682 . 105. Feuvray D and Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury:

the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 1997;34:113-120. 106. Feuvray D, Lopaschuk GD. Diabetes mellitus and the cardiocascular system. Cardiovasc Res 1997;34:1-

2. 107. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic

heart. Cardiovasc Res 1997;34:125-133. 108. Gamble J and Lopaschuk GD. Insulin inhibition of 5’adenosine monophosphate-activated protein kinase

in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation.

CV

Metabolism 1997;46:1270-1274. 109. Lopaschuk GD. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial

ischemia. Am J Cardiol 1997;80:11A-16A. 110. Belke DD, Wang L, Lopaschuk GD. Acetyl-CoA carboxylase control of fatty acid oxidation in hearts

from hibernating Richardson’s ground squirrels. Biochim Biophys Acta 1998;1391: 25-36. 111. Dyck JRB and Lopaschuk GD. Glucose metabolism, H+ production and Na+/H+ exchanger mRNA levels

in ischemic hearts from diabetic rats. Mol Cell Biochem 1998;180: 85-93. 112. Shangraw E Rabkin, Lopaschuk GD. Hepatic pyruvate dehydrogenase activity in humans: Effects of

cirrhosis, transplantation and dichlororacetate. Am J Physiol 1998;37:G569-G577. 113. Ford W, Clanachan AS, Lopaschuk GD, Schulz R, Jugdutt BI. Intrinsic Ang II type 1 receptor stimulation

contributes to recovery of post-ischemic mechanical junction. Am J Physiol 1998;43:H1524-H1531.

114. Ford W, Lopaschuk GD, Schulz RS, Clanachan AS. KATP-channel activation: effects on myocardial recovery to adenosine A1-receptor stimulation. Br J Pharmacol 1998;124:639-646.

115. Liu Q, Clanachan AS, Lopaschuk GD. Acute effects of triiodothyronine on glucose and fatty acid

metabolism during reperfusion of ischemic rat hearts. Am J Physiol 1998;275:H392-H399. 116. Fraser H, Lopaschuk GD, Clanachan AS. Assessment of glycogen turnover in aerobic, ischemic and

reperfused working rat hearts. Am J Physiol 1998;275:H1533-H1541.

117. Dyck JRB, Barr A, Barr R, Kolattukudy PE, Lopaschuk GD. Characterization of cardiac malonyl-CoA decarboxylase and its putative role in regulating fatty acid oxidation. Am J Physiol 1998;275:H2122-H2129.

118. Makinde AO, Kantor PF, Lopaschuk GD. Maturation of fatty acid and carbohydrate metabolism in the

newborn heart. Mol Cell Biochem 1998;188:49-56. 119. Saiki Y, Lopaschuk GD, Dodge K, Yamaya K, Morgan C, Rebeyka IM. Pyruvate augments mechanical

function via activation of the pyruvate dehydrogenase complex in reperfused ischemic immature rabbit hearts. J Surg Res 1998;79:164-169.

120. Kantor PF, Robertson MA, Coe JY, Lopaschuk GD. Volume overload hypertrophy of the newborn heart

slows the maturation of enzymes involved in the regulation of fatty acid metabolism. J Am Coll Cardiol 1999;33:1724-1734.

121. Larsen TS, Belke DD, Dani R, Giles WR, Severson DL, Lopaschuk GD, Tyberg JV. The Isolated

working mouse heart: methodological considerations. Pflugers Archives Eur J Physiol 1999;437:979-985.

122. Bergman BC, Butterfield GE, Wolfel EE, Casazza GA, Lopaschuk GD. Brooks, G.A. An evaluation of

exercise and training on muscle lipid metabolism. Am J Physiol 1999;276:E106-E117. 123. Voilley N, Roduit R, Vicaretti R, Bonny C, Waeber G, Dyck JRB, Lopaschuk GD, Prentki, M. Cloning

and expression of rat pancreatic -cell malonyl-CoA decarboxylase. Biochem J 1999;340:213-217.

CV

124. Bergman BC, Butterfield GE, Wolfel EE, Casazza GA, Lopaschuk GD, Brooks GA. Muscle net glucose uptake and glucose kinetics after endurance training in men. Am J Physiol 1999;277:E81-E92.

125. Dyck JRB, Kudo N, Barr AJ, Davies SP, Hardie G, Lopaschuk GD. Phosphorylation control of cardiac

acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase. Eur J Biochem 1999;262:184-190.

126. Belke DD, Larsen TS, Lopaschuk GD and Severson DL. Glucose and fatty acid metabolism in the

isolated working mouse heart. Am J Physiol 1999;277:R1210-R1217. 127. Fraser H, Lopaschuk GD, Clanachan AS. Alterations and glucose metabolism in ischaemic and post-

ischaemic working rat hearts by adenosine A1 receptor stimulation. Br J Pharmacol 1999;128:197-205. 128. Kline JA, Thornton LR, Lopaschuk GD, Barbee RW and Watts JA. Heart function after severe

hemorrhagic shock. Shock 1999;12:411-490. 129. Bergman BC, Wolfel EE, Butterfield GE, Lopaschuk GD, Casazza GA, Horning MA, Brooks GA. Active

muscle and whole body lactate kinetics after endurance training in men. J Appl Physiol 1999;87:1684-1696.

130. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopaschuk GD, Allard, M.F. Glucose utilization

and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. J Mol Cell Cardiol 1999;31:493-502.

131. Sakamoto J, Barr RL, Kavanagh KM, Lopaschuk GD. Contribution of malonyl-CoA decarboxylase to the

high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol 2000;278:H1196-H1204. 132. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The anti-anginal drug trimetazidine shifts cardiac energy

metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3-ketoacyl CoA thiolase. Circ Res 2000;86:580-588.

133. Kline JA, Thornton LR, Lopaschuk GD, Barbee RW, Watts JA. Lactate improves cardiac efficiency after

hemorrhagic shock. Shock 2000;14:215-221. 134. Dyck JRB, Berthiaume L, Kantor PF, Barr AJ, Singh D, Hopkins TA, Voilley N, Prentki M, Lopaschuk

GD. Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochem J 2000;350:599-608.

135. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopaschuk GD, Allard M. Dichloroacetate

improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 2000;36:1378-1385. 136. Ford WR, Jugdutt BI, Lopaschuk GD, Schulz R and Clanachan AS. Influence of beta-adrenoreceptor tone

on the cardioprotective efficacy of adenosine A(1) activation in isolated working rat hearts. Br J Pharmacol 2000;131:537-545.

137. Barr R, Lopaschuk GD. Methodology for measuring in vitro/ex vivo cardiac energy metabolism. J.

Pharmacol Toxicol Methods 2000;43:141-152.

138. Taniguchi M, Wilson C, Hunter CA, Pehowich D, Clanachan AS, Lopaschuk GD. Dicholoroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. Am J Physiol 2001;280:H1762-H1769.

CV

139. Custalow CC, Watts JA, Lopaschuk GD. Role of fatty acids in the recovery of cardiac function during resuscitation from hemorrhagic shock. Shock 2001;15:231-238.

140. Longnus SL, Wambolt RB, Barr RL, Lopaschuk GD, Allard MF. Regulation of myocardial fatty acid

oxidation by substrate supply. Am J Physiol 2001;281:H1561-H1567. 141 Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R,

Lopaschuk GD, Kelly DP. The cardiac phenotype induced by PPAR overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-130.

142. Liu Q, Docherty JC, Rendell JCT, Clanachan AS, Lopaschuk GD. High levels of fatty acid delay the recovery of intracellular pH and cardiac efficiency in postischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 2002;39:718-725.

143. Michelakis ED, McMurtry MS, Wu XC, Dyck JRB, Moudgil R, Hopkins T, Lopaschuk GD, Archer SA. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 2002;105:244-250.

144. Lopaschuk GD, Rebeyka IM, Allard MF. Metabolic Modulation: A means to mend a broken heart.

Circulation 2002;105:140-142. 145. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JRB, Belke DD, Severson DL, Kelly DP,

Lopaschuk GD. A role for peroxisome proliferator-activated receptor (PPAR in the control of cardiac malonyl CoA levels. J Biol Chem 2002;277:4098-4103.

146. Recchia FA, Osorio JC, Chandler MP, Xu X, Panchal AR, Lopaschuk GD, Hintze TH, Stanley WC.

Reduced synthesis of NO causes marked alterations in myocardial substrate metabolism in conscious dogs. Am J Physiol 2002;282:E197-E206.

147. Leong HS, Grist M, Parsons H, Wambolt RB, Lopaschuk GD, Brownsey R, Allard MF. Accelerated rates

of glycolysis in the hypertrophied heart: Are they a methodological artifact? Am J Physiol 2002;282:E1039-E1045.

148. Atkinson LA, Kelly SE, Russell JC, Bar-Tana J, Lopaschuk GD. MEDICA 16 inhibits hepatic acetyl-

CoA and reduces plasma triacylglycerol levels in insulin resistant JCR:LA-cp rats. Diabetes 2002;51:1548-1555.

149. Xu Y, Kumar D, Dyck JRB, O’Brien DW, Ford WR, Clanachan AS, Lopaschuk GD, Jugdutt BI. AT(1)

and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts. Am J Physiol 2002;282:H1206-H1215.

150. Atkinson LA, Fischer MA, Lopaschuk GD. Leptin activated cardiac fatty acid oxidation independent of

changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl CoA axis. J Biol Chem 2002;277:29424-29430

151. Osorio JC, Stanley WC, Linke A, Castellari M, Diep ON, Panchan AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106: 606-612 .

152. Dyck JRB and Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol

Cell Cardiol 2002;34:1099.

CV

153. Besikci A, Campbell FM, Hopkins TA, Dyck JRB, Lopaschuk GD. Relative importance of malonyl CoA

and carnitine in the maturation of fatty acid oxidation in the newborn rabbit heart. Am J Physiol 2003;284:H283-H289.

154. Atkinson LL, Kozak R, Kelly SE, Onay-Besikci A, Russell JC, Lopaschuk GD. Potential mechanisms

and consequences of cardiac triacylglycerol accumulation in insulin resistant rats. Am J Physiol 2003;284:E923-E930.

155. Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JR, Lopaschuk GD, Control of cardiac pyruvate

dehydrogenase activity in peroxisome proliferator-activated receptor- transgenic mice. Am J Physiol 2003;285:H270-H276.

156. Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working

ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003;93:E33-E37.

157. Stanley WC, Meadows SR, Kivilo KM, Roth BA, Lopaschuk GD. -hydroxybutyrate inhibits

myocardial fatty acid oxidation in vivo independent of changes in malony-CoA content. Am J Physiol 2003;285:H1631-H1631.

158. Bamford JA, Lopaschuk GD, MacLean IM, Reinhart ML, Dixon WT, Putman CT. Effects of chronic

AICAR administration on the metabolic and contractile phenotypes of rat slow- and fast-twich skeletal muscle. Can J Physiol 2003;81:1072-1082.

159. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Pucetti P, Calori G, Lopaschuk G.D. Short- and

long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:18.

160. Kuang M, Febbraio M, Wagg C, Lopaschuk GD, Dyck JRB. Fatty acid translocase/CD36 deficiency does

not energetically or functionally compromise hearts before or after ischemia. Circulation 2004;109:1550-1557 .

161. Lopaschuk GD. Glutamate transport in the heart: lessons learned from the brain. J Mol Cell Cardiol 2004;37:5-6.

162. Zhou D, Yuen P, Chu D, Thon V, McConnell S, Brown S, Tsang A, Pena M, Russell A, Cheng JF, Nadzan AM, Barbosa MS, Dyck JRB, Lopaschuk GD, Yang G. Expression, purification and characterization of human malonyl-CoA decarboxylase. Protein Expression & Purification 2004;34:261-269.

163. Reszko AE, Kasumov T, David F, Thomas KR, Jobbins KA, Cheng JF, Lopaschuk GD, Dyck JRB, Diaz

M DesRosiers C, Stanley WC, Brunengraber H. Regulation of malonyl-CoA concentration and turnover in the normal heart. J Biol Chem 2004;279:34298-34301.

164. Sambandam N, Steinmetz M, Chu A, Altarejos JY, Dyck JRB, Lopaschuk GD. Malonyl-CoA

decarboxylase (MCD) is differentially regulated in subcellular compartments by 5’AMP-activated protein kinase (AMPK). Studies using H9c2 cells overexpressing MCD and AMPK by adenoviral gene transfer technique. Eur J Biochem 2004;271:2831-2840.

165. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, Brown S, Wallace D, Arhenios T, Harmon C,

Yang G, Nazdan AM, Lopaschuk GD. Malonyl coenzyme a decarboxylase inhibition protects the

CV

ischemic heart by inhibiting fatty acid oxidation and glucose oxidation. Circ Res 2004;194:E78-E84. 166. Onay-Besikci A, Altarejos JY, Lopaschuk GD. gAd-globular head domain of adiponectin increases fatty

acid oxidation in newborn rabbit hearts. J Biol Chem 2004;279:44320-44326. 167. T Abou-Rjaily GA, Al-share QY, Yang Y, Fenstrom MA, De Angelis AM, Lee AD, Sweetman L, Amato

A, Pasquale M, Lopaschuk GD, Erickson SK, Najjar SM. Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. J Biol Chem 2004;279:45155-45161.

168. León H, Atkinson L, Sawicka J, Strynadka K, Lopaschuk GD, Schulz R. Pyruvate prevents cardiac

dysfunction and AMP-activated protein kinase activation by hydrogen peroxide in isolated rat hearts. Can J Physiol Pharmacol 2004;82:409-416.

169. Altarejos JY, Taniguchi M, Clanachan AS, Lopaschuk GD. Myocardial ischemia differentially regulates

LKB1 and an alternate 5’AMP-activated protein kinase kinase. J Biol Chem 2005;280:183-190. 170. Sheth SS, Castellani LW, Chari S, Wagg C, Thipphavong CK, Bodnar JS, Tontonoz P, Attie AD,

Lopaschuk GD, Lusis AJ. Thioredoxin interacting protein (Txnip) deficiency disrupts the fasting-feeding metabolic transition. J Lipid Res 2005;46:123-134 .

171. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing

heart. Physiol Rev 2005;85:1093-1129. 172. Al-Hesayen A, Azevedo ER, Floras JS, Hollingshead S, Lopaschuk GD and Parker JD. Selectiveversus

nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 2005;7:618-623.

173. King KL, Okere IC, Sharma N, Dyck JR, Reszko AE, McElfresth T, Kerner J, Candler MP, Lopaschuk

GD, Stanley WC. Regulation of cardiac malonyl-CoA content and fatty acid oxidation during increased cardiac power. Am J Physiol 2005;289:H1033-H1037.

174. Stanley WC, Morgan EE, Huang H, McElfresh T, Sterk JP, Okere IC, Chandler MP, Cheng J, Dyck JR,

Lopaschuk GD. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demand-induced ischemia. Am J Physiol 2005;289:H2304-H2309.

175. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD. Chronic activation of

PPAR is detrimental to cardiac recovery after ischemia. Am J Physiol 2006;290:H87-H95. 176. Degrado TR, Kitapci MT, Wang S, Ying J, Lopaschuk GD. Validation of 18F-fluoro-4-thia-palmitate as

PET probe for myocarcial fatty acid oxidation: Effects of hypoxia and composition of exogenous fatty acid. J Nucl Med 2006;47:173-181.

177. Cheng JF, Chen M, Wallace D, Tith S, Haramura M, Liu B, Mak CC, Arrhenius T, Reily S, Brown S,

Thorn V, Harmon C, Barr R, Dyck JRB, Lopaschuk G, Nadzan AM. Synthesis and structure – activity relationship of small-molecule malonyl Coenzyme A decarboxyase inhibitors. J Med Chem 2006;49:1517-1525.

178. Huang W, Dedousis N, Bandi A, Lopaschuk GD, O’Doherty RM. Liver triglyceride secretion and lipid

oxidative metabolism are rapidly altered by leptin in vivo. Endocrinology 2006;147:1480-1487. 179. Collier CA, Bruce CR, Smith AC, Lopaschuk GD, Dyck JRB. Metformin counters the insulin-induced

suppression of fatty acid oxidation and stimulation of triacylglycerol storage in rodent skeletal muscle.

CV

Am J Physiol 2006;291:E182-E189. 180. Folmes CL, Clanachan AS, Lopaschuk GD. Fatty acids attenuate insulin regulation of 5'-AMP-activated

protein kinase and insulin cardioprotection after ischemia. Circ Res 2006;99:61-68. 181. Dyck JR and Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J

Physiol 2006;574:95-112 . 182. Lopaschuk GD. Cardiac energy metabolism alterations in angiostein II induced hypertrophy. J Moll Cell

Cardiol 2006;41:418-420. 183. Cheng JF, Huang Y, Penuliar R, Nishimoto M, Liu L, Arrhenius T, Yang G, O'leary E, Barbosa M, Barr

R, Dyck JR, Lopaschuk GD, Nadzan AM. Discovery of potent and orally available malonyl-CoA decarboxylase inhibitors as cardioprotective agents. J Med Chem 2006;49:4055-4058 .

184. Fragasso G, Montano C, Perseghin G, Palloshi A, Calori G, Lattuada G, Oggionni S, Bassanelli G,

Locatelli M, Lopaschuk GD, Margonato A. The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition. Am Heart J 2006;151:1238.E1-E8.

185. Cheng JF, Mak CC, Huang Y, Penuliar R, Nishimoto M, Zhang L, Chen M, Wallace D, Arrhenius T, Chu

D, Yang G, Barbosa M, Barr R, Dyck JR, Lopaschuk GD, Nadzan, A.M. Heteroaryl substituted bis-trifluoromethyl carbinols as malonyl-CoA decarboxylase inhibitors. Bioorg Med Chem Lett 2006;16:3484-3488.

186. Noga AA, Soltys CL, Barr AJ, Kovacic S, Lopaschuk GD, Dyck JR. Expression of an active LKB1

complex in cardiac myocytes results in decreased protein sunthesis associated with phenylephrine-induced hypertrophy. Am J Physiol 2006;292:H1460-H1469.

187. Dyck JRB, Hopkins TA, Bonnet S, Michelakis E, Young ME, Watanabe Y, Kawase Y, Jishage, K.,

Lopaschuk GD. Absence of malonyl CoA decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006;114:1721-1728.

188. Lopaschuk GD and Stanley W. Malonyl-CoA decarboxylase inhibition as a novel approach to treat

ischemic heart disease. Cardiovasc Drugs Ther 2006;20:433-439. 189. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD,

Puttagunta L, Bonnet SN, Harry G, Hashimoto K, Thebaud B, Michelakis E. A Mitochondria-K+ Channel Axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.

190. Putnam CT, Martins KJ, Gallo ME, Lopaschuk GD, Pearcey JA, Maclean Im, Saranchuk RJ, Pette D. {alpha}-Catalytic subunits of 5’AMP-activated protein kinase display fiber specific expression and are upregulated by chronic low-frequency stimulation in rat muscle. Am J Physiol 2007;293:R1325-R1334.

191. Szczesna-Cordary D, Jones M, Moore JR, Watt J, Kerrick WG, Wu Y, Wang Y, Wagg C, Lopaschuk GD.

Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients. FASEB J 2007;21:3974-3985.

192. Wallis GA, Friedlander AL, Jacobs KA, Horning MA, Fattor JA, Wolfel EE, Lopaschuk GD, Brooks

GD. Substantial working muscle glycerol turnover during two-legged cycle ergometry. Am J Physiol 2007;293:E950-E957.

CV

193. Gao S, Kinzig KP, Aja S, Scott KA, Keung W, Kelly S, Strynadka K, Chohan S, Smith WW, Tamashiro, KL, Ladenheim EE, Ronnett GV, Tu Y, Birnbaum MJ, Lopaschuk GD, Moran TH. Leptin activates hypothalamic acetyl-CoA carboxylase to inhibit food intake. Proc Natl Acad Sci 2007;104: 17358-17363.

194. Zhou L, Huang H, Yuan CL, Keung W, Lopaschuk GD, Stanley WC. Metabolic response to an acute

jump in cardiac workload: effects on malonyl-CoA, mechanical efficiency, fatty acid oxidation. Am J Physiol 2007;294: H954-H960.

195. Onay-Besikci A, Wagg C, Lopaschuk TP, Keung W, Lopaschuk GD. Alpha-lipoic acid increases cardiac glucose oxidation independant of AMP-activated protein kinase in isolated working rate hearts. Basic Res Cardiol 2007;102:436-444 .

196. Carley AN, Atkinson LL, Bonen A, Harper ME, Kunnathu S, Lopaschuk GD, Severson DL. Mechanisms responsible for enhanced fatty acid utilization by perfused hearts from type 2 diabetic db/db mice. Arch Physiol Biochem 2007;113:65-75.

197. Lopaschuk GD, Folmes C, Stanley W. Cardiac energy metabolism in obesity. Circ Res 2007;102:335-

347.

198. Koves TR, Ussher JR, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck J, Newgard CB, Lopaschuk GD and Muoio DM. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metabolism 2008;7:45-56.

199. Khairallah RJ, Khairallah M, Gelinas R, Bouchard B, Young ME, Allen BG, Lopaschuk GD, Deschepper CF, Des Rosiers C. Cyclic GMP signaling in cardiomyocytes modulates fatty acid trafficking and prevents triglyceride accumulation. J Mol Cell Cardiol 2008;45:230-239.

200. Lopaschuk GD, Kelly DP. Signalling in Cardiac Metabolism. Cardiovasc Res 2008;79:205-207. 201. Lei B, Chess DJ, Keung W, O’Shea KM, Lopaschuk GD, Stanley WC. Transient activation of P38 MAP

kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008;45:404-410.

202. Yatscoff MA, Jaswal JS, Grant MR, Greenwood R, Lukat T, Beker DL, Rebeyka IM, Lopaschuk GD.

Myocardial hypertrophy and the maturation of fatty acid oxidation in the newborn human heart. Ped Res 2008;64:643-647.

203. Fert-Bober J, Sawicki G, Lopaschuk GD, Cheung PY. Proteomic analysis of cardiac metabolic enzymes

in asphyxiated newborn piglets. Mol Cell Biochem 2008;318:13-21.

204. Wang L, Lopaschuk GD, Clanachan AS. H(2)O(2)-induced left ventricular dysfunction in isolated working rat hearts is independent of calcium accumulation. J Mol Cell Cardiol 2008;45: 787-795.

205. Ussher JR and Lopaschuk GD. The malonyl CoA axis as a potential target for treating ischemic heart

disease. Cardiovasc Res 2008;79:259-268

206. Abraham TP, Jones M, Kazmierczak K, Liang HY, Pinheiro AC, Wagg CS, Lopaschuk GD, Szczesna-Cordary D. Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice. Cardiovasc Res 2009;82:84-92.

207. Folmes CD, Sowah D, Clanachan AS, Lopaschuk GD. High rates of fatty acid oxidation during mild

CV

ischemia decreases cardiac work and efficiency. J Mol Cell Cardiol 2009;47:142-148. 208. Wang X, Chow FL, Oka T, Hao L, Lopez-Campistrous A, Kelly S, Cooper S, Odenbach J, Finegan BA,

Schulz R, Kassiri A, Lopaschuk GD. and Fernandez-Patron, C. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 2009;119:2480-2489.

209. Folmes CD, Wagg CS, Shen M, Folmes, Clanachan AS, Tian R, Lopaschuk GD. Suppression of AMP-

activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts. Am J Physiol 2009;297:H313-H321.

210. Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in

mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009;119:2818-2828.

211. Ussher JR, Koves TR, Jaswal JJ, Zhang L, Ilkayeva O, Dyck JR, Muoio DM, Lopaschuk GD. Insulin-

stimulated cardiac glucose oxidation is increased in high fat diet- induced obese mice lacking malonyl CoA decarboxylase. Diabetes 2009;58:1766-1765.

212. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C.

Tumor Necrosis Factor {alpha}-Converting Enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension 2009;54:575-582.

213. Ussher JR, Jaswal JJ, Wagg CS, Armstrong HE, Keung W, Lopaschuk GD. Role of the atypical protein

kinase Czeta in regulation of 5’-AMP-activated protein kinase in cardiac and skeletal muscle. Am J Physiol 2009;297:E349-E57 .

214. Ussher JR, Lopaschuk GD. Targeting malonyl CoA inhibition of mitochondrial fatty acid uptake as an

approach to treat cardiac ischemia/reperfusion. Basic Res Cardiol 2009;104:203-210. 215. Basu R, Oudit GY, Wang X, Ussher JR, Lopaschuk GD, Kassiri, Z. Type 1 diabetic cardiomyopathy in

the Akita (Ins2WT/C96Y) mouse model is characterized by diastolic dysfunction with preserved systolic function. Am J Physiol 2009;297:H2096-H2108.

216. Zhang L, Keung W, Samokhvalov V, Wang W and Lopaschuk GD. Role of fatty acid uptake and fatty

acid beta-oxidation in mediating insulin resistance in heart and skeletal muscle. Biochim Biophys Acta 2010;1801:1-22 .

217. Piao L, Fang YH, Cadete V, Wietholt C, Urboniene D, Toth P, Marsboom G, Zhang H, Haber I, Rehman

J, Lopaschuk GD, Archer S. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electric remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med 2010;88:47-60.

218. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS. and Stanley WC. Myocardial fatty acid metabolism in

health and disease. Physiol Rev 2010;90:207-258. 219. Carvalho RA, Sousa RPB, Cadete VJJ, Lopaschuk GD, Palmeira CMM, Bjork JA and Wallace KB.

Metabolic remodeling associate with subchronic doxorubicin cardiomyopathy. Toxicology 2010;270:92-98.

220. Ito M, Jaswal JS, Lam VH, Oka T, Zhang L, Beker DL, Lopaschuk GD and Rebeyka IR. High levels of

fatty acids increase contractile function of neonatal rabbit hearts during reperfusion following ischemia.

CV

Am J Physiol 2010;298:H1426-1437 . 221. Niu W, Bilan PJ, Ishikura S, Schertzer JD, Contreras-Ferrat A, Fu Z, Liu J, Boguslavsky S, Foley KP, Liu

Z, Li J, Chu G, Panakkezhum T, Lopaschuk GD, Lavandero S, Yao Z, Klip A. Contraction-related stimuli regulate GLUT4 traffic in C2C12-GLUT4 myc skeletal muscle cells. Am J Physiol 2010;298:E1058-E1071 .

222. Lopaschuk GD, Ussher JR and Jaswal JS. Targeting intermediary metabolism in the hypothalamus as a

mechanism to regulate appetite. Pmcol Rev 2010;62:237-264. 223. Jessen N, Koh HJ, Folmes, C.D, Wagg C, Fujii N, Lofgren B, Wolf CM, Berul CI, Hirschman MF,

Lopaschuk, GD. and Goodyear, LJ. Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta 2010;1802: 593-600.

224. Ussher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ, Lopaschuk DG, Proctor SD, Keung W,

Muoio DM, Lopaschuk GD. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole body oxygen consumption. Diabetes 2010;59:2453-2464.

225. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JRB and Michelakis

ED. Fatty acid oxidation and malonyl CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Science (Trans Med) 2010;11:44ra58.

226. Scott JM, Esch BT, Haykowsky MJ, Paterson I, Warburton DE, Chow K, Baron JC, Lopaschuk GD and

Thompson RB. Effects of high intensity exercise on biventricular function assessed by cardiac magnetic resonance imagin gin endurance training and normally active individuals. Am J Cardiol 2010;106:278-283.

227. Folmes CD, Sawicki G, Cadete VJ, Masson G, Barr AJ and Lopaschuk GD. Novel O-palmitolylated beta

E1 subunit of pyruvate dehydrogenase is phosphorylated during ischemia/ reperfusion injury. Proteome Sci 2010;8:38.

228. Dolinsly VW, Morton JS, Oka T, Robillard-Fraynem I, Bagdan M, Lopaschuk GD, Des Rosiers C, Walsh

K, Davidge ST and Dyck JRB. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010;56:412-421.

229. Jaswal JS, Lund CR, Keung W, Beker DL, Rebeyka IR and Lopaschuk GD. Isoproterenol stimulates 5’-

AMP activated protein kinase and fatty acid oxidation in neonatal hearts. Am J Physiol 2010;299:H1135-1145 .

230. Wang L, Ko KWS, Lucchinetti E, Zhang L, Troxler H, Hersberger M, Omar MA, Posse de Chaves EI,

Lopaschuk GD, Clanachan AS and Zaugg M. Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation. Anesthesiology 2010;113:541-551.

231. Kandalam V, Basu R, Abraham T, Wang X, Awad A, Wang W, Lopaschuk GD, Maeda N, Oudit GY and Kassiri Z. Early activation of matrix metalloproteinases underlies the exacerbated systolic

and diastolic dysfunction in mice lacking TIMP3 following myocardial infarction. Am J Physiol 2010;299:H101-H1023.

232. Keung W, Cadete VJ, Palaniyappan A, Jablonski A, Fischer M and Lopaschuk GD. Intracerebroventrical

leptin administration differentially alters cardiac energy metabolism in mice fed a low fat and high fat diet. J Cardiovasc Pharmacol 2010;57:103-113.

CV

233. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk GD, Kassirir Z and Fernandez-Patron C.

MMP-2 mediates angiotensinII-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension 2010;57:123-130.

234. Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, Finck BN and Kelly DP.

Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem 2011;286:11155-11162.

235. Mraiche F, Wagg CS, Lopaschuk GD and Fliegel L. Elevated levels of activated NHE1 protect the

myocardium and improve metabolism following ischemia/ reperfusion injury. J Mol Cell Cardio 2011;50:157-164.

236. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in

high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 2011;89:148-56.

237. Rueda-Clausen CF, Morton JS, Lopaschuk GD and Davidge ST. Long-term effects of intrauterine growth

restriction on cardiac metabolism and susceptibility to ischemia reperfusion. Cardiovasc Res 2011;90:285-294.

238. Jaswal JS, Keung W, Wang W, Ussher JR, Lopaschuk GD. Targeting fatty acid and carbohydrate

oxidation--a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 2011;1813:1333-50

239. Lucchinetti E, Wang L, Ko KW, Troxler H, Hersberger M, Zhang L, Omar MA, Lopaschuk GD,

Clanachan AS, Zaugg M. Enhanced glucose uptake via GLUT4 fuels recovery from calcium overload after ischaemia-reperfusion injury in sevoflurane- but not propofol-treated hearts. Br J Anaesth 2011;106:792-800.

240. Kudej RK, Fasano M, Zhao X, Lopaschuk GD, Fischer SK, Vatner DE, Vatner SF, Lewandowski ED.

Second window of preconditioning normalizes palmitate use for oxidation and improves function during low-flow ischaemia. Cardiovasc Res 2011;92:394-400.

241. Keung W, Palaniyappan A, Lopaschuk, GD. Chronic central leptin decreases food intake and improves

glucose tolerance in diet-induced obese mice independent of hypothalamic malonyl CoA levels and skeletal muscle insulin sensitivity. Endocrinology 2011;152:4127-37.

242. Gao S, Keung W, Serra D, Wang W, Carrasco P, Cassals N, Hegardt FG, Moran TH and Lopaschuk GD.

Malonyl-CoA mediates leptin hypothalamic control of feeding independent of inhibition of CPT-1a. Am J Physiol 2011;301:R209-R217.

243. Gao S, Zhu G, Gao X, Wu D, Carrasco P, Casals N, Hegardt FG, Moran TH and Lopaschuk GD.

Important roles of brain-specific carnitine palmitoyltransferase and ceramide metabolism in leptin hypothalamic control of feeding. Proc Natl Acad Sci USA 2011;108:9691-9696.

244. Axelsen LN, Keung W, Pedersen HD, Meier E, Riber D, Kjølbye AL, Petersen JS, Proctor SD, Holstein-

Rathlou NH, Lopaschuk GD. Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts. Br J Pharmacol 2012;165:2736-48.

245. Lopaschuk GD and Jaswal JS. Hypoxia-induced adaptation to mitral regurgitation: a role for K ATP

CV

channel up-regulation? J Am Coll Cardiol 2012;59:397-9. 246. Oka T, Lam VH, Zhang L, Keung W, Cadete VJ, Samokhvalov V, Tanner BA, Beker DL, Ussher JR,

Huqi A, Jaswal JS, Rebeyka IM and Lopaschuk GD. Cardiac hypertrophy in the newborn delays the maturation of fatty acid β-oxidation and compromises post-ischemic functional recovery. Am J Heart Circ Physiol 2012;302:H1784-H1794.

247. Zhang L, Mori J, Wagg C and Lopaschuk GD. Activating cardiac E2F1 induces up-regulation of pyruvate

dehydrogenase kinase 4 in mice on a short term of high fat feeding. FEBS letters 2012;586:996-1003. 248. Lopaschuk GD and Ussher JR. An ACE up your sleeve: 2 is better than 1. Circ Res 2012;10:1270-1272. 249. Ussher JR, Wang W, Ghandi M, Keung W, Samokhvalov V, Oka T, Wagg CS, Jaswal JS, Harris RA,

Clanachan AS, Dyck JD and Lopaschuk GD. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 2012;94:359-369.

250. Borthwick F, Warnakula S, Mangat R, Russell JC, Kelly Se, Lee CY, Hryshko L, Mamo JC, Rye KA,

Lopaschuk GD and Proctor SD. ApoA-1 infusion reduces arterial cholesterol and myocardial lesionsin a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis 2012;222:402-408.

251. Ussher JR, Folmes CD, Keung W, Fillmore N, Jaswal JS, Cadete VJ, Beker DL, Lam VH, Zhang L and

Lopaschuk GD. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance. PLoS One 2012;7:E37703.

252. Cadete VJ, Sawicka J, Jaswal J, Lopaschuk GD, Schulz RS, Szczena-Cordary D and Sawicki G.

Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases is degradation by matrix metalloproteinase-2. FEBS J 2012;279:2444-2454.

253. Ussher, J.R., Jaswal, J.S. and Lopaschuk, G.D. Pyridine nucleotide regulation of cardiac intermediary

metabolism. Circ. Res. 111:628-641 (2012). 254. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z, Lopaschuk GD and Oudit

GY. Agonist-induced hypertrophy and diastolic dysfunction is associated with selective reduction in glucose oxidation: A metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fall 2012;5:493-503.

255. Lopaschuk GD and Jaswal JS. A role for period 2 in cardioprotection. Cell Metab 2012;16:2-4. 256. Lopaschuk GD. The challenge of treating diastolic heart failure. Heart Metabolism 2012;57:1-2. 257. Fillmore N and Lopaschuk GD. How the heart relaxes. Heart Metabolism 2012;57:1-4. 258. Samokhvalov V, Ussher JR, Fillmore N, Armstrong IK, Keung W, Moroz D, Lopaschuk DG, Seubert,

JM, Lopaschuk GD. Inhibition of malonyl CoA decarboxylase reduces the inflammatory response associated with insulin resistance. Am J Physiol Endocrinol Metab 2012;303:E1459-1468.

259. Cherian S, Lopaschuk GD, Carvalho E. Cellular cross-talk between epicardial adipose tissue and

myocardium in relation to the pathogenesis of cardiovascular disease. Am J Physiol Endocrinol Metab 2012;303:E937-949.

260. Jaswal JS, Ussher JR, Lopaschuk GD, Johnstone DE. Something old holds potential to be something new

in heart failure: Allopurinol revisited. Can J Cardiol 2012;28:626-628.

CV

261. Fillmore N, Lopaschuk GD. Targeting mitochondrial oxidative metabolism as an approach to treat heart

failure. Biochim Biophys Acta 2013;1833:857-865. 262. Keung W, Ussher J, Jaswal J, Raubenheimer M, Lam V, Wagg C, Lopaschuk G. Inhibition of carnitine

palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice. Diabetes 2013;62:711-720.

263. Wu G, Zhang L, Li T, Lopaschuk GD, Vance DE and Jacobs RL. Choline deficiency attenuates body

weight gain and improves glucose tolerance in ob/ ob mice. J Obesity 2013;288:837-847. 264. Wu G, Zhang L, Li T, Lopaschuk GD, Jacobs R, Vance DE. Choline supplementation promotes hepatic

insulin resistance in phosphatidylethanolmine N-methyltransferase-deficient mice via increased glucagon action. J Biol Chem 2013;288: 837-847.

265. Lewandowski ED, Fischer SK, Fasano M, Banke NH, Walker LA, Huqi A, Wang X, Lopaschuk GD,

O'Donnell JM. Acute L-CPT1 overexpression recapitulates reduced palmitate oxidation of cardiac hypertrophy. Circ Res 2013;112:57-65.

266. Zhabyeyev P, Gandhi M, Mori J, Basu R, Kassiri Z, Clanachan A, Lopaschuk GD, Oudit GY. Pressure-

overload induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. Cardiovac Res 2013;97:676-685.

267. Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD,

Archer SL. FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med 2013;91:333-346.

268. Lee D, Oka T, Hunter B, Robinson A, Papp S, Nakamura K, Srisakuldee W, Nickel BE, Light PE, Dyck

JR, Lopaschuk GD, Kardami E, Opas M and Michalak M. Calreticulin induces dilated cardiomyopathy. PLoS One 2013;8(2):e56387 .

269. Mori J, Alrob OA, Wagg CS, Harris RA, Lopaschuk GD and Oudit GY. Ang II causes insulin resistance

and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 2013;304:H1103-1113.

270. Gill R, Lee TF, Manouchehri N, Liu JQ, Lopaschuk G, Bigam DL and Cheung PY. Postresuscitation

cyclosporine treatment attenuates myocardial and cardiac mitochondrial injury in newborn piglets with asphyxia-reoxygenation. Crit Care Med 2013;41:1069-1074.

271. Singh KK, Shukla PC, Yanagawa B, Quan A, Lovren F, Pan Y, Wagg CS, Teoh H, Lopaschuk GD. and

Verma S. Regulating cardiac energy metabolism and bioenergetics by targeting the DNA damage repair protein BRCA1. J Thorac Cardiovasc Surg 2013;146:702-709.

272. Gao S, Serra D, Keung W, Hegardt FG, Lopaschuk GD. Important role of ventromedial hypothalamic

carnitine palmitoyltransferase-1a in the control of food intake. Am J Physiol Endocrinol Metab 2013;305:E336-347.

273. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS,

Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 2013;1832:1723-1733.

CV

274. Gao S, Casals N, Keung W, Moran TH, Lopaschuk GD. Differential effects of central ghrelin on fatty acid metabolism in hypothalamic ventral medial andarcuate nuclei. Physiol Behav 2013;118:165-170.

275. Ussher J and Lopaschuk GD. Cardiac insulin resistance: It’s sweeter than you think. Endocrinology

2013;154:2575-2578. 276. Mori J, Zhang L, Oudit GY, Lopaschuk GD. Impact of the renin-angiotensin system on cardiac energy

metabolism in heart failure. J Mol Cell Cardiol 2013;63:98-106. 277. Zhang L, Jaswal JS, Ussher JR, Sankaralingam S, Wagg C, Zaugg M, Lopaschuk GD. Cardiac insulin

resistance and decreased mitochondrial energy production precede the development of systolic heart failure following pressure overload hypertrophy. Circ Heart Fail 2013;6:1039-1048.

278. Shrivastav S, Zhang L, Okamoto K, Lee H, Lagranha C, Abe Y, Balasubramanyam A, Lopaschuk GD,

Kino T, Kopp JB. HIV-1 Vpr enhances PPARβ/δ-mediated transcription,increases PDK4 expression and reduces PDC activity. Mol Endocrinol 2013;27:1564-1576.

279. Ussher JR, Lopaschuk GD, Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis. 2013;231:456-61. 280. Gao S, Moran TH, Lopaschuk GD, Butler AA. Hypothalamic malonyl-CoA and the control of food intake. Physiol Behav 2013;122:17-24. 281. Zhang L, Yu X, Cheypesh A, Rebeyka IM, Granoski D, Lopaschuk GD, Li J. Plasma fatty acid levels in

children during extracorporeal membrane oxygenation support-a pilot study. J Extra Corpor Technol 2013;45(4):242-247.

283. Masoud WG, Ussher JR, Wang W, Jaswal JS, Wagg CS, Dyck JR, Lygate CA, Neubauer

S, Clanachan AS, Lopaschuk GD. Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res 2014;101:30-38.

284. Lopaschuk GD, Keehan KH, Taegtmeyer H, Des Rosiers C, William (Bill) C Stanley (1957-2013). Am J

Physiol Heart Circ Physiol 2014;306:H161-2. 285. Mori J, Patel VB, Abo Alrob O, Basu R, Altamimi T, Desaulniers J, Wagg CS, Kassiri Z, Lopaschuk GD,

Oudit GY. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 2014;7:327-339.

286. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure,

ischemic heart disease, and diabetic cardiomyopathy. Br J Pharmacol 2014;8:2080-2090. 287. Fillmore N and Lopaschuk GD. Malonyl CoA: A promising target for the treatment of cardiac disease.

IUBMB Life. 2014; Mar 3. doi: 10.1002/iub.1253. [Epub ahead of print] PubMed PMID: 24591219. 288. Mori J, Patel VB, Ramprasath T, Alrob OA, Desaulniers J, Scholey JW, Lopaschuk GD, Oudit GY. Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation and lipotoxicity. Am J Physiol Renal Physiol 2014;306:F812-F821. 289. Lee CT, Ussher JR, Mohammad A, Lam A, Lopaschuk GD. 5'-AMP-activated protein kinase increases

glucose uptake independent of GLUT4 translocation in cardiac myocytes. Can J Physiol Pharmacol 2014;92:307-314 .

CV

290. Ussher JR, Keung W, Fillmore N, Koves TR, Mori J, Zhang L, Lopaschuk DG, Ilkayeva OR, Wagg CS, Jaswal JS, Muoio DM, Lopaschuk GD. Treatment with the 3-Ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice. J Pharmacol Exp Ther 2014;349(3):487-96.

291. Davidson SM, Lopaschuk GD, Spedding M, Beart PM. Mitochondrial pharmacology: energy, injury and

beyond. Br J Pharmacol 2014;171(8):1795-7. 292. Samokhvalov V, Alsaleh N, El-Sikhry HE, Jamieson KL, Chen CB, Lopaschuk DG, Carter C, Light PE,

Manne R, Falck JR, Seubert JM. Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response. Cell Death Dis 2014;4:e885.

293. Gao S, McMillan RP, Jacas J, Zhu Q, Li X, Kumar GK, Casals N, Hegardt FG, Robbins PD, Lopaschuk

GD, Hulver MW, Butler AA. Regulation of substrate oxidation preferences in muscle by the peptide hormone a dropin. Diabetes 2014;63:3242-3252.

294. Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L. Cardiovascular remodelling in

coronary artery disease and heart failure. Lancet 2014;383:1933-1943. 295. Abo Alrob O and Lopaschuk GD. Role of CoA and acetyl-CoA in regulating cardiac fatty acid and glucose oxidation. Biochem Soc Trans 2014;42(4):1043-51. 296. Ussher JR, Fillmore N, Keung W, Mori J, Beker DL, Wagg CS, Jaswal JS,

Lopaschuk GD. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice. Can J Cardiol 2014;30(8):940-4.

297. Ezekowitz JA, Becher H, Belenkie I, Clark AM, Duff HJ, Friedrich MG, Haykowsky

MJ, Howlett JG, Kassiri Z, Kaul P, Kim DH, Knudtson ML, Light PE, Lopaschuk GD, McAlister FA, Noga ML, Oudit GY, Paterson DI, Quan H, Schulz R, Thompson RB, Weeks SG, Anderson TJ, Dyck JR. The Alberta Heart Failure Etiology and Analysis Research Team (HEART) study. BMC Cardiovasc Disord 2014;14(1):91.

298. Alrob OA, Sankaralingam S, Ma C, Wagg CS, Fillmore N, Jaswal JS, Sack MN,

Lehner R, Gupta MP, Michelakis ED, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD. Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovasc Res 2014;103(4):485-97.

299. Fillmore N, Lopaschuk GD. The link between pediatric heart failure and mitochondrial lipids. J. Mol.

Cell Cardiol 2014;76C:71-72. 300. Aksentijević D, McAndrew DJ, Karlstädt A, Zervou S, Sebag-Montefiore L, Cross,

R, Douglas G, Regitz-Zagrosek V, Lopaschuk GD, Neubauer S, Lygate CA. Cardiac dysfunction and peri-weaning mortality in malonyl-coenzyme A decarboxylase (MCD) knockout mice as a consequence of restricting substrate plasticity. J Mol Cell Cardiol 2014;75:76-87.

301. Putko BN, Wang Z, Lo J, Anderson T, Becher H, Dyck JR, Kassiri Z, Oudit GY;

Alberta HEART Investigators. Circulating levels of tumor necrosis factor-alpha receptor 2 are increased in heart failure with preserved ejection fraction relative to heart failure with reduced ejection fraction: evidence for a divergence in pathophysiology. PLoS One 2014;9(6):e99495.

302. Wu R, Chang HC, Khechaduri A, Chawla K, Tran M, Chai X, Wagg C, Ghanefar M,

CV

Jiang X, Bayeva M, Gonzalez F, Lopaschuk GD, Ardehali, H. Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy. J Clin Invest 2014;3;124(11):4795-806.

303. Zhang L, Yu X, Cheypesh A, Rebeyka IM, Granoski D, Lopaschuk, G.D, Li J. Plasma fatty acid levels in children during extracorporeal membrane oxygenation support - a pilot study. J Extra Corpor Technol 2014;45(4):242-7. 304. Wu R, Chang HC, Khechaduri A, Chawla K, Tran M, Chai X, Wagg C, Ghanefar M, Jiang X, Bayeva M, Gonzalez F, Lopaschuk GD, Ardehali H. Cardiac-specific ablation of ARNT leads to lipotoxicity and cardiomyopathy. J Clin Invest 2014;124(11):4795-806. 305. Sankaralingam S, Alrob OA, Zhang L, Jaswal JS, Wagg CS, Fukushima A, Padwal RS, Johnstone DE, Sharma AM, Lopaschuk GD. Lowering body weight in obese mice with diastolic heart failure improves cardiac insulin sensitivity and function: Implications for the obesity paradox. Diabetes 2015;64:1643-1657. 306. Lopaschuk GD, Ussher JR. Targeting microRNAs to limit myocardial lipid accumulation. Circ Res

2015;116(2):229-31. 307. Fillmore N, Huqi A, Jaswal JS, Mori J, Paulin R, Haromy A, Onay-Besikci A, Ionescu L, Thébaud B,

Michelakis E, Lopaschuk GD. Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival. PLoS One 2015;10(3):e0120257.

308. Mohamed IA, Gadeau AP, Fliegel L, Lopaschuk GD, Mlih M, Abdulrahman N, Fillmore N, Mraiche F.

Na+/H+ exchanger isoform 1-induced osteopontin expression facilitates cardiomyocyte hypertrophy. PLoS One. 2015;10(4):e0123318.

309. Gao S, McMillan RP, Zhu Q, Lopaschuk GD, Hulver MW, Butler AA. Therapeutic effects of adropin on

glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol Metab 2015;4(4):310-24 .

310. Fillmore N, Keung W, Kelly SE, Proctor SD, Lopaschuk GD, Ussher JR. Accumulation of ceramide in

slow-twitch muscle contributes to the development of insulin resistance in the obese JCR:LA-cp rat. Exp. Physiol 2015;100(6):730-741.

311. Opie LH, Lopaschuk GD. What is good for the circulation also lessens cancer risk. Eur0 Heart J

2015;36(19):1157-1162. 312. Sankaralingam S, Lopaschuk, GD. Cardiac energy metabolic alterations in pressure overload-induced left

and right heart failure. Pulm Circ 2015;5(1):15-28. 313. Lam VH, Zhang L, Huqi A, Fukushima A, Tanner BA, Onay-Besikci A, Keung W, Kantor PF, Jaswal

JS, Rebeyka IM, Lopaschuk GD. Activating PPARα prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts. Circ Res 2015;117:41051.

314. Patel VB, Mori J, McLean BA, Basu R, Das SK, Ramprasath T, Parajuli N, Penninger JM, Grant MB,

Lopaschuk GD, Oudit GY. ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity. Diabetes 2015 Jul 29. pii: db150399. [Epub ahead of print] PubMed PMID: 26224885.

315. Fukushima A, Milner K, Gupta A, Lopaschuk GD. Myocardial energy substrate metabolism in heart

failure : from pathways to therapeutic targets. Curr Pharm Des 2015 Jul 10. [Epub ahead of print]

CV

PubMed PMID: 26166604. 316. Masoud WG, Abo Al-Rob O, Yang Y, Lopaschuk GD, Clanachan AS. Tolerance to ischaemic injury in

remodelled mouse hearts: less ischaemic glycogenolysis and preserved metabolic efficiency. Cardiovasc Res. 2015 Sep 1;107(4):499-508

317. Azam MA, Wagg CS, Massé S, Farid T, Lai PF, Kusha M, Asta J, Jaimes R 3rd, Kuzmiak-Glancy S, Kay

MW, Lopaschuk GD, Nanthakumar K. Feeding the fibrillating heart: Dichloroacetate improves cardiac contractile dysfunction following VF. Am J Physiol Heart Circ Physiol 2015 Nov;309(9):H1543-53

318. Patel VB, Mori J, McLean BA, Basu R, Das SK, Ramprasath T, Parajuli N, Penninger JM, Grant MB,

Lopaschuk GD, Oudit GY. ACE2 Deficiency Worsens Epicardial Adipose Tissue Inflammation and Cardiac Dysfunction in Response to Diet-Induced Obesity. Diabetes 2016 Jan;65(1):85-95

319. Akhnokh MK, Yang FH, Samokhvalov V, Jamieson KL, Cho WJ, Wagg C, Takawale A, Wang X,

Lopaschuk GD, Hammock BD, Kassiri Z, Seubert J. (2016). Inhibition of soluble epoxide hydrolase limits mitochondrial damage and preserves function following ischemic injury. Front Pharmacol. 7(133): 1-7.

320. Groenendyk J, Lee D, Jung J, Dyck JR, Lopaschuk GD, Agellon LB, Michalak M. (2016). Inhibition of

theunfolded protein response mechanism prevents cardiac fibrosis. PLoS One. 11(7): e0159682. 321. Lopaschuk GD. (2016). Fatty acid oxidation and its relation with insulin resistance and associated

disorders. Annals of Nutrition and Metabolism. 68((suppl 3)): 15-20. 322. Carvalhoi E, Lopaschuk GD, Borsheim E, Burgeiro A. (2016). Reply to Katlander, Ozbek and Keser.

Am J Physiol: Endocrinol Metab. 310(10): E863. 323. Ussher JR, Fillmore N, Keung W, Zhang L, Mori J, Sidhu VK, Fukushima A, Gopal K, Lopaschuk DG,

Wagg CS, Jaswal JS, Dyck JR, Lopaschuk GD. (2016). Genetic and pharmacological inhibition of malonyl CoA decarboxylase does not exacerbate age-related insulin resistance in mice. Diabetes. 65(7): 1883-1893.

324. Taegtmeyer H, Young ME, Lopaschuk GD, Stanley WC, Neubauer S, Gropler R, Malloy C, Des

Rosiers C, plus 19 authors American Heart Statement: Assessing cardiac metabolism. Circ Res A scientific statement from the American Heart Association.Circulation Research. 118(10): 1659-1701.

325. Lopaschuk GD, Verma S. (2016). Empagliflozin's fuel hypothesis: Not so soon. Cell Metabolism.

9(24): 200-202. 326. Lopatin YM, Rosano GM, Fragasso G, Lopaschuk GD, Seferovic PM, Gowdak LH, Vineranu D, Hamid

MA, Jourdain P, Ponikowski P. (2016). Rationale and benefits of trimetazidine by acting on cardiac 327. Lopaschuk GD. (2016). Preface to the BBA special issue "heart lipid metabolism". Biochim Biophys

Acta.1860(10): 1423-1424. 328. Fukushima A, Alrob OA, Zhang L, Wagg CS, Altamimi T, Rawat S, Rebeyka IM, Kantor PF,

Lopaschuk GD. (2016). Acetylation and succinylation contribute to maturational alterations in energy metabolism in the newborn heart. Am J Physiol: Heart and Circulatory Physiology. 311(2): H347-H363.

329. Fukushima A, Lopaschuk GD. (2016). Acetylation control of cardiac fatty acid ß-oxidation and energy

CV

metabolism in obesity, diabetes and heart failure. Biochim Biphys Acta. S0925-4439(16): 30188-0. 330. Lopaschuk GD, Ussher JR. (2016). Evolving concepts of myocardial energy metabolism: More than fats

and carbohydrates. Circulation Research. 119(8): 1-5. 331. Fukushima A, Lopaschuk GD.(2016). Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim Biophys Acta. 1860(10): 1525-34.

CV

BOOK CHAPTERS AND INVITED PAPERS: 1. Lopaschuk, G.D. Glucose oxidation in hearts from diabetic rats perfused following a period of transient

global ischemia. In: Diabetic Heart, eds: Nagano M and Dhalla NS, Raven Press Ltd p. 451-464 (1991). 2. Lopaschuk, G.D., Broderick T., and Saddik, M. In: Carnitine and carnitine acyltransferase inhibitors

stimulate glucose oxidation in intact hearts perfused with high concentration of acids. In: Current concepts in carnitine research. ed. Carter AL, CRC Press, 231-243 (1992).

3. Lopaschuk, G.D. Effects of carnitine and carnitine acyltransferase inhibition on energy substrate

utilization in the intact heart. L-carnitine and its role in medicine from function to therapy, ed. R. Ferrari, Academic Press. 22:.403-410 (1991).

4. Lopaschuk, G.D. and Saddik, M. The relative contribution of glucose and fatty acids to ATP production

in hearts reperfused following ischemia. Mol. Cell. Biochem. 116:111-116 (1992). 5. Lopaschuk, G.D., Collins-Nakai, R.L., and Itoi, T. Developmental changes in energy substrate use by

the heart. Cardiovasc. Res. 26:1172-1180(1992). 6. Lopaschuk, G.D., Broderick T., and Gamble, J. Pharmacological control of glucose and fatty acid

metabolism in the heart. Cardiologia 37(suppl):29-33 (1992). 7. Schönekess, B.O., and Lopaschuk, G.D. The effects of carnitine on myocardial carbohydrate metabolism.

The Carnitine System and the Heart. Ed: J.W. de Jung, R. Ferrari pp. 39-52 (1995). 8. Clanachan, A.S., and Lopaschuk, G.D. Alterations in energy substrate metabolism during oxidative

stress. Purines and Myocardial Protection. Abd-Alfattah & Wechsler Eds. Kluwer Academic Publishers, pp. 105-115 (1996)

9. Lopaschuk, G.D. How can fatty acid and carbohydrate metabolism be manipulated? Dialogues in

Cardiovascular Res. 1:93-98 (1996) 10. Barr, R.L., Lopaschuk, G.D. The fatty acid perfused isolated working heart “Measurement of

Cardiovascular Function”, Ed. J.H. McNeill, CRC Press pp. 1-17 (1997). 11. Barr, R.L., Lopaschuk, G.D. Direct measurement of energy metabolism in the isolated working rat heart.

J. Pharmacol. Toxicol. Methods. 38:11-17(1997). 12. Lopaschuk, G.D., Barr, R. Measurements of fatty acid and carbohydrate metabolism in the isolated

working rat heart. Mol. Cell. Biochem. 172:137-147(1997). 13. Lopaschuk, G.D., Stanley, W.C. Manipulations of energy metabolism in the heart. Sci. & Med. 4:42-51

(1997) 14. Barr, R.L., Lopaschuk, G.D. Measurements of energy metabolism in the isolated heart. “Measurement of

Cardiovascular Function”, Ed. J.H. McNeill, CRC Press 19-40 (1997). 15. Lopaschuk, G.D. Carnitine and myocardial glucose metabolism. Carnitine Today 71-93 (1997) 16. Lopaschuk, G.D. Alterations in fatty acid oxidation during reperfusion of the heart after myocardial

ischemia. Am. J. Cardiol. 80:11A-16A (1997)

CV

17. Lopaschuk, G.D., Barr, R. Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol. Cell. Biochem. 172:137-147 (1997)

18. Lopaschuk, G.D., Stanley, W.C. Manipulation of energy metabolism in the heart. Science and Medicine.

4:2-51 (1997) 19. Belke, D.D., Lopaschuk, G.D. Fatty acid metabolism in the reperfused ischemic heart. Advances

inLipobiology, JAI Press Inc. 2:29-46 (1997) 20. Lopaschuk, G.D. Advantages and limitations of experimentala techniques used to measure cardiac energy

metabolism. J. Nucl. Cardiol. 4:316-328 (1997). 21. Lopaschuk, G.D., Clanachan, A.S. The source and fate of protons in the reperfused ischemic heart. “The

Ischemic Heart” Kluwer Academic Publishers. S. Mochiuzuki, N. Takeda, M. Nagano, N. Dhalla Eds.199-213 (1998)

22. Lopaschuk, G.D. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. “Presse Med.” 27:2100-2104(1998) French.

23. Lopaschuk, G.D. Fatty acid and gluccose metabolism: A target for intervention. “Metabolic Management

of Ischemic Heart Disease”. Am. J. Cardiol. SP Science Press Ltd. 44-54 (1998) 24. Makinde, A.O., Kantor, P.F., Lopaschuk, G.D. Maturation of fatty acid and carbohydrate metabolism in

the newborn heart. Mol. Cell. Biochem. 188:49-56 (1998). 25. Stanley W.C., Lopaschuk, G.D., Kivilo, K.M. Alteration in myocardial energy metabolism in

streptozotocin diabetes. Experimental Models of Diabetes. CRC Press (1999). 26. Kantor, P.F., Dyck, J.R.B., Lopaschuk, G.D. Fatty acid oxidation in the reperfused ischemic

heart. Am. J. Med. Sci. 318:3-14 (1999) 27. Lopaschuk, G.D. Optimizing cardiac energy metabolism: a new approach to treating ischaemic heart

disease. Eur. Heart J. Suppl. 1:32-39 (1999) 28. Lopaschuk, G.D. Metabolic agents: a new approach to the management of coronary heart disease. Heart

and Metabolism 5:1-2 (1999) 29. Lopaschuk, G.D. Metabolic agents: a new approach in treating ischemic heart disease. Heart and

Metabolism 4:5-10 (1999) 30. Lopaschuk, G.D. Métabolisme énergétique du coeur diabétique: Effets de l’ischémie et de

l’hypertrophie. In Coeur et Diabète. Prise en charge et suivi des patients diabétiques. Ed. Frison-Roche. pp. 31-50 (1999).

31. Kantor, P.F., Dyck, J.R., Lopaschuk, G.D. Fatty acid oxidation in the reperfused ischemic heart. Am. J.

Med. Sci. 318:3-14 (1999).

32. Lopaschuk, G.D. Regulation of Carbohydrate metabolism in ischemia and reperfusion. Am. Heart J. 139:S115-S119 (1999).

33. Allard, M.F., Stanley, W.A., Lopaschuk, G.D. Metabolic effects of glucose-insulin-potassium on the

CV

heart. Heart and Metabolism 7:2-9 (2000). 34. Lopaschuk, G.D. Glycolysis Regulation. Encyclopedia of Sciences 1-11 (2000). 35. Kantor, F.P., Lopaschuk, G.L., Opie, L.H. Myocardial Energy Metabolism. Heart Physiology and

Pathophysiology. 534-569 (2000) 36. Lopaschuk, G.D. Myocardial metabolism and function in diabetes. Heart and Metabolism, 11:3-7 (2001). 37. Marber, M., Lopaschuk, G.D. Metabolic and ion flux interventions for acute infarction? Heart and

Metabolism, 12:1-2 (2001) 38. Lopaschuk, Gary D. Optimizing cardiac energy metabolism: How can fatty acid and carbohydrate

metabolism be manipulated? Coronary Artery Disease, 12:S8-S11 (2001). 39. Lopaschuk, G.D. Myocardial metabolism and function in diabetes. Heart and Metabolism 11:3-7 (2001). 40. Lopaschuk, G.D. Trimetazidine in AMI. Eur. Heart J. 22:977-978 (2001). 41. Lopaschuk, G.D. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am. Heart. J.

139:S115-119 (2001). 42. Lopaschuk, G.D. Malonyl CoA control of fatty acid oxidation in the diabetic rat heart. Diabetes and

Cardiovascular Disease. 498:155-165 (2001). 43. Lopaschuk, G.D. Metabolic abnormalities in the diabetic heart. Heart Failure Reviews 7:149-159 (2002). 44. Sambandam N., Lopaschuk, G.D., Brownsey, R.W., Allard, M.F. Energy metabolism in the hypertrophied

heart. Heart Fail. Rev. 7:161-173 (2002). 45. Lopaschuk, G.D. Metabolic Modulation in the management of coronary artery disease. Cardiology at the

limits.17-34 (2002). 46. Lopaschuk, G.D., Opie, L.H. Introduction to JMCC Symposium on myocardial energy metabolism in

health and disease. J. Mol. Cell. Cardiol. 34:1075-1076 (2002).

47. Lopaschuk, G. Mode of action of trimetazidine and other new metabolic agents in the treatment of ischemic heart disease. Proceedings: Low Output Syndrome Revisited. 77-81 (2002).

48. Lopaschuk, G. Metabolic modulation in the management of coronary artery disease. Cardiology at the

Limits V. 17-30 (2002). 49. Lopaschuk, G.D. Pharmacological rationale for trimetazidine in the treatment of ischemic heart disease.

Am. J. Cardiov. Drugs 3 (Suppl. 1):21-26, 2003. 50. Lopaschuk G.D. Metabolic Interventions. Acute Coronary Syndromes, Saunders. 359-367 (2003).

51. Dyck, J.R.B., Lopaschuk, G.D. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J. Mol.

Cell. Cardiol. 34:1099 (2002). 52. Sambandam, N., Lopaschuk, G.D., Brownsey, R.W., Allard, M.E. Energy metabolism in the

hypertrophied heart. Heart Fail. Rev. 7:161-173 (2002).

CV

53. Hopkins, T.A., Dyck, J.R.B, Lopaschuk, G.D. AMP-activated protein kinase regulation of fatty acid

oxidation in the ischaemic heart. Biochem. Soc. Trans. 31:207-212 (2003). 54. Sambandam, N., Lopaschuk, G.D. AMP-activated protein kinase control of fatty acid and glucose

metabolism in the ischemic heart. Prog. Lipid Res. 42:238-256 (2003) 55. Lopaschuk, G.D., Marzilli, M. Mode of action of trimetazidine and other new metabolic agents in the

treatment of ischemic heart disease. Seminars in Cardiothoracic and Vascular Anesthesia. 7:91-96 (2003).

56. Lopaschuk, G.D. Manipulation of free fatty acid oxidation in ischemic heart disease. Medicographia

25:334-340 (2003). 57. Lopaschuk, G.D. Hypertrophic Cardiomyopathies: role of genetic mutations in proteins involved in

sarcomere function and energy metabolism in the pathogenesis of this disorder. Heart Metab. 21:3-4 (2003).

58. Opie, L.H., Lopaschuk, G.D. Fuels: Aerobic and Anaerobic Metabolism. Heart Physiology. From Cell to

Circulation. Lipincott Williams and Wilkins 306-354 (2003) 59. Lopaschuk, G., Onay-Besikci A. Regulation of fatty acid oxidation by malonyl CoA in cardiac muscle.

Lipobiology 33:223-24 (2004). 60. Lopaschuk G.D. Targets for modulation of fatty acid oxidation in the heart. Current Opinion in

Investigational Drugs 5:290-294 (2004). 61. Fukao, T., Lopaschuk, G.D., Mitchell, G.A. Pathways and control of ketone body metabolism: on the

fringe of lipid biochemistry. Prostaglandins Leuk. Essent. Fatty Acids 70:243-251 (2004). 62. Lopaschuk, G.D. The role of fatty acid oxidation in cardiac ischemia. Adv. Studies Med. 4:S803-S807

(2004). 63. Lopaschuk, G. Glutamate transport in the heart: lessons learned from the brain. J. Mol. Cell Cardiol.

37:1:5-6 (2004).

64. Noga, A.A., Dyck, J.R.B., Lopaschuk, G.D. Alterations in energy metabolism in acute coronary syndromes. Heart Metab. 23:5-12 (2004).

65. Armstrong, P.W, Ezekowitz, C., Michelakis, E., Anderson, T., Archer, S., Ghali, W., Hayward, R.,

Jensen, L. Lopaschuk, G.D., Sheldon, R. Innovative strategic Canadian research training from Tomorrow’s Research Cardiovascular Health Care Professionals (TORCH). Clin. Invest. Med. 27:33- 341 (2004).

66 Folmes, C.D.L., Clanachan, A.S., Lopaschuk, G.D. Fatty acid oxidation inhibitors in the management of

chronic complications of atherosclerosis. Current Atherosclerosis Reports 7:63-70 (2005). 67. Lopaschuk, G.D. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart

failure. Seminars in Cardiothoracic and Vascular Anesthesia. 3:28-230 (2006). 68. Lopaschuk, G.D. Cardiac energy metabolism alterations in angiotensin II induced hypertrophy. J. Mol.

Cell. Cardiol. 41:418-420 (2006).

CV

69. Ussher, J.R., Lopaschuk, G.D. Clinical implications of energetic problems in cardiovascular diseases.

Heart and Metabolism. Metabolic Profile in Heart Disease. 32:9-17 (2006). 70. Lopaschuk, G.D., Stanley, W. Malonyl-CoA decarboxylase inhibition as a novel approach to treat

ischemic heart disease. Cardiovasc. Drugs. Ther. 20:433-439 (2006).

71. Lopaschuk G.D. Optimizing cardiac fatty acid and glucose metabolism as an approach to treating heart failure. Semin. Cardiothorac. Vasc. Anesth. 10:228-230 (2006)

72. Folmes, C., Lopaschuk, G.D. Role of malonyl CoA in heart disease and the hypothalamic control of

obesity. Cardiovascular Research. Spotlight issue in Nutrition and Metabolism. 73:278-287 (2007). 73. Lam, A., Lopaschuk, G. Anti-anginal effects of partial fatty acid oxidation inhibitors. Curr Opin

Pharmacol. 7:179-82 (2007). 74. Lopaschuk, G.D. Cardiac metabolism I. Dialogues in Cardiovascular Medicine. 3:278-87 (2007). 75. Noga, A.A., Soltys, C.M., Barr, A.J., Kovacic, S., Lopaschuk, G.D., Dyck, J.R. Expression of an active

LKB1 complex in cardiac myocytes results in decreased protein synthesis associated with phenylephrine-induced hypertrophy. Am. J. Physiol. 292:H1460-H1469 (2007).

76. Taha, M., Lopaschuk, G.D. Alterations in energy metabolism in cardiomyopathies. Ann. Med.39: 594-607 (2007).

77. Wang, W., Lopaschuk, G.D. Metabolic therapy for the treatment of ischemic heart disease: reality and

expectations. Expert Review of Cardiovascular Therapy 21:3974-3985 (2007). 78. Jaswal J.S., Cadete V.J.J., Lopaschuk G.D. Optimizing cardiac energy substrate metabolism: a novel

therapeutic intervention for ischemic heart disease. Heart Metab. 38: 5-14 (2008). 79. Lopaschuk, G.D. AMP-activated protein kinase control of energy metabolism in the ischemic heart. Int J

Obes (Lond) 4:S29-S35 (2008). 80. Lopaschuk, G.D. Editorial. Diabetes and cardiovascular disease. Heart Metab. 45 (2009). 81. Jaswal, J.S., Ussher, J.R., Lopaschuk, G.D. Myocardial fatty acid utilization as determinant of cardiac

efficiency and function. Clin. Lipid. 4:379-389 (2009). 82. Lopaschuk, G.D., Jaswal, J.S. Energy metabolic phenotype of the cardiomyocyte during development,

differentiation, and post-natal maturation. J. Cardio. Pharmacol 56:130-140 (2010). 83. Lopaschuk, G.D. Editorial. Obesity and heart disease. Heart Metab. 48 (2010). 84. Jaswal, J.S., Keung, W., Wamg, W., Ussher, J.R. and Lopaschuk, G.D. Molecular changes in fatty acid

oxidation in the failing heart. In: Molecular defects in cardiovascular disease. eds: Dhalla, N., Nagano, M. and Ostadal, B. Springer p.153-176 (2011).

85. Jaswal, J.S. and Lopaschuk, G.D. Cardiac energy metabolism in ischemia and ischemic cardiomyopathy.

In: Moving forward on the management of ischemic cardiomyopathy. eds: Ferrari, R. and Ponikowski, P. Springer p.55-72 (2011).

CV

86. Nagoshi, T., Yoshimura, M., Rosano, G.M., Lopaschuk, G.D., Mochizuki, S. Optimization of cardiac metabolism in heart failure. Curr. Pharm. Des. 17:3846-53 (2011)

87. Fillmore, N., Abo Alrob, O. and Lopaschuk, G.D. Fatty acid beta-oxidation. AOCS Lipid Library. [Epub

ahead of print] (2011). 88. Lopaschuk, G.D. Editorial. Dictionary of Cardiac Metabolism, Heart Metab. Servier (2012). 89. Lopaschuk, G.D. Cardiac energy metabolism in heart failure associated with obesity and diabetes. In:

Cardiac Energy Metabolism in Health and Disease. Editors: Lopaschuk G., Dhalla N.S.; Springer, New York p. 89-102 (2014).

90. Altamimi R., Lopaschuk, G.D. Role of carnitine in modulation of muscle energy metabolism and insulin

resistance. In: Carnitine Metabolism and Human Nutrition. Editors: Wall B.T., Porter C. CRC Press, Boca Raton, Florida (in press).

Abstracts: 339